

**REVIEW**

# *Myroxylon pereirae* resin (balsam of Peru) – A critical review of the literature and assessment of the significance of positive patch test reactions and the usefulness of restrictive diets

Anton C. de Groot acdegroot publishing, Wapserveen,  
The Netherlands**Correspondence**Dr Anton C. de Groot, acdegroot publishing,  
Schipsootweg 5, 8351 HV Wapserveen,  
The Netherlands.  
Email: antondegroot@planet.nl

In this article, contact allergy to *Myroxylon pereirae* resin (MP) (balsam of Peru) is reviewed. The topics presented include the uses, the chemical composition, the frequency of sensitization, the relevance of positive reactions, the MP-containing products causing allergic contact dermatitis, co-reactivity with other fragrance and non-fragrance materials, the sensitizers, the usefulness of MP as a “marker” of fragrance allergy, and the effectiveness of, and indications for, “balsam-restrictive” diets. Sensitization to MP occurs in 4% to 8% of patients routinely tested for suspected contact dermatitis. There are few adequate data on relevance. Topical pharmaceuticals were formerly, but are not today, important sources of sensitization. Cosmetics and foods or drinks are hardly ever products responsible for sensitization to MP. Positive patch test reactions in the large majority probably result from previous sensitization to MP constituents because of their presence in fragrances and fragranced products, MP thereby acting as marker (or “indicator”) of fragrance allergy. However, fragrance mix I is a more sensitive marker, and the added diagnostic value of testing with MP is unknown. The allergenic ingredients of MP include isoeugenol, eugenol and cinnamyl alcohol, but there are other—largely unknown—chemicals that are responsible for contact allergy. Suggestions are given for further research to address questions thus far unanswered and to improve patient care.

**KEYWORDS**balsam of Peru, balsam-restrictive diet, chemical composition, eugenol, cinnamyl alcohol, coniferyl benzoate, fragrance, isoeugenol, *Myroxylon pereirae* resin, perfume, fragrance marker, contact allergy

## 1 | INTRODUCTION

*Myroxylon pereirae* resin (MP) is a botanical balsam that has a long history of medicinal use, especially as an antiseptic and for wound healing. Bonnevie, at the Finsen Institute in Copenhagen, began routine testing with MP in 1939 to detect sensitization to topical preparations containing the balsam.<sup>1</sup> Since the 1960s, MP has been used as a marker for fragrance sensitivity, as it was discovered that half of the patients with positive reactions to MP are also sensitive to one or more toilet soap perfumes and vice versa.<sup>2–4</sup>

In this article, various aspects of contact allergy to MP are reviewed, including its chemical composition, the frequency of sensitization, the sensitizers, the relevance of positive reactions, the MP-containing products causing allergic contact dermatitis, the use of restrictive diets in patients reacting to MP, and co-reactivity with other fragrance and non-fragrance materials. An attempt is made to establish the significance of positive patch test reactions to MP and the value of testing MP in the baseline series. This article is an abbreviated but strongly adapted version of the chapter “*Myroxylon pereirae* resin (balsam of Peru)” published in the author’s book *Monographs in*

Contact Allergy, Volume II—Fragrances and Essential Oils.<sup>5</sup> The literature on contact allergy to MP up to 1961 was reviewed by Hjorth in his famous PhD Thesis “Eczematous allergy to balsams.”<sup>2</sup>

### 1.1 | What is *Myroxylon pereirae* resin?

MP (INCI name United States *Myroxylon pereirae* (balsam Peru) resin; balsam Peru; balsam of Peru; Peruvian balsam; CAS no. 8007-00-9; EC number 232-352-8) is the balsam obtained from the bark of *Myroxylon balsamum* (L.) Harms var. *pereirae* (Royle) Harms. This tree grows between 300 and 700 m above sea level in the coastal regions of El Salvador and also in Nicaragua, Honduras, Guatemala, Cuba, Mexico, Costa Rica, and Panama.<sup>3,6-8</sup>

To remove the bark from the tree, it is alternately scorched and beaten. The balsam in the bark is obtained by boiling. Following removal of strips of bark from the tree, the exposed wood also secretes balsam. This material is absorbed into rags wrapped around the tree, which are then boiled in water. The balsam sinks to the bottom and is then collected.<sup>7</sup> Crude MP is a dark brown, viscous liquid that is transparent and yellowish-brown when viewed in a thin layer. It has an aromatic smell of cinnamon and vanilla, and a bitter taste. The name balsam of Peru is misleading. Most MP in worldwide circulation comes from El Salvador, not Peru, where the source tree does not grow. The misnomer does not originate, as is often stated, from El Salvador belonging to the Viceroyalty of Peru in the 16th century, but from the fact that, at that time, the Spanish originally packed and shipped the balsam to Europe from the port of Callao in Lima, Peru, one of the main ports of that time in the New World.<sup>9</sup>

### 1.2 | Uses

MP has a long history of medicinal use. In the 17th century, the “drug” appeared in German pharmacies. It was included in the United States Pharmacopeia from 1820, and MP has been described in many other national pharmacopoeias. Indications for its topical use have included chronic ulcers, poorly healing wounds, decubitus, eczema, pruritus, haemorrhoids and anal pruritus (in the form of rectal suppositories), scabies (later replaced with its ingredient benzyl benzoate), frostbite, nappy rash, and intertrigo. However, in 2016 the European Medicines Agency concluded that “There is no documentation available for Peru balsam to support a well-established use indication.”<sup>10</sup>

The main buyers of pure MP are or were pharmaceutical companies, perfume manufacturers, the food industry, and stores selling natural or herbal products. MP as a complete mixture has been replaced more and more by single constituents or fractions of MP that are now used in foods, sweets, bakery goods, chocolate, pastries, and medicinal ointments.<sup>11</sup> MP or its ingredients may also be added, or have been added, to tobacco. Formerly, MP was present in many topical pharmaceuticals, for example, in countries such as France, Denmark and Belgium. Currently, however, it is not used in such products in Denmark,<sup>12</sup> and it is only rarely used in Belgium.<sup>13</sup>

Crude MP as such has not been used in perfumery and, as a consequence, not in perfumes in cosmetics, since 1982 (or 1974?<sup>14</sup>),

when the International Fragrance Association (IFRA) banned its use in fragrances.<sup>15-17</sup> The possibility that some cosmetic products contain MP as a non-fragrance ingredient cannot be excluded, but, as the sensitizing properties have been well known for decades, it seems unlikely that many cosmetic manufacturers would use it. Indeed, in February 2019, MP was present in only 6 of 70 893 (0.008%) cosmetic products for which the composition is known in the Skin Deep Cosmetics Database of the Environmental Working Group (EWG), United States.<sup>18</sup> Extracts or distillates are allowed, and the current IFRA Standard restricts the use of these products to a level of 0.03% to 0.7% in consumer products, depending on the product category.<sup>19</sup> However, neither material is used at high volumes, and the “oil” was present in only 17 of 70 893 (0.02%) cosmetic products in the United States.<sup>18</sup> Whether these products are<sup>17</sup> or are not<sup>16,20</sup> less allergenic than the crude material is controversial, but, with EC3 values in the murine local lymph node assay of 4% for the oil and 2.5% for the absolute,<sup>17</sup> these materials are still “weak-to-moderate” sensitizers.

## 2 | CHEMICAL COMPOSITION

Surprisingly little information is available on the qualitative and quantitative chemical composition of MP and its derivatives (oil, essential oil, and absolute).<sup>2,6,7,11,17,21</sup> The oleoresin is said to contain some 250 ingredients with a resin content of 20% to 40%<sup>2,6</sup>; the rest is a high-boiling volatile oil (often incorrectly called “essential oil”) named cinnamein (which is also a synonym for benzyl cinnamate).<sup>22</sup> The quantitatively most important chemicals in MP appear to be benzyl cinnamate (up to 40%), benzyl benzoate (up to 30%), cinnamic acid (3%-30%), benzoic acid (1.5%-11%), coniferyl benzoate (only in fresh MP up to 8.5% [probably a mistake, should be 1.5%<sup>5</sup>]), nerolidol (2%-7%), benzyl alcohol (1%-2%), vanillin (0.2%-1.3%), cinnamyl cinnamate (0.5%), cinnamyl alcohol (0.4%), ferulic acid (0.1%-0.4%), benzyl isoferulate (0.2%), and coniferyl alcohol (0.2%).<sup>6,11</sup> These and other ingredients of MP or its derivatives identified with gas chromatography, gas chromatography-mass spectrometry or other analytical methods are shown in Table 1.<sup>2,6,7,11,17,21,23</sup> The concentrations for most are not mentioned, as they have been presented as percentages of various fractions of MP, have been identified in MP derivatives (the composition of which greatly depends on the mode of production), or have been identified only qualitatively. In contrast to what is often stated, cinnamal does not appear to be an ingredient of MP (products). According to the European Pharmacopeia, MP should contain 45% to 70% mass/mass of esters, mainly benzyl benzoate and benzyl cinnamate.<sup>24</sup>

MP derivatives used in perfumery are prepared either by vacuum distillation (Peru balsam oil) or by solvent extraction (Peru balsam absolute/oil); it can also be hydrodistilled to obtain Peru balsam essential oil. In nearly all materials, the most important chemicals are benzyl benzoate (at least half of the composition), benzyl cinnamate, cinnamic acid, benzoic acid, *E*-nerolidol, benzyl alcohol, and vanillin.<sup>21,23,25</sup> In one investigation, nerolidol was the major constituent in a hydrodistilled essential oil sample and in an oil obtained by solid-phase micro-extraction.<sup>7</sup>

**TABLE 1** Ingredients identified in *Myroxylon pereirae* resin (MP), extracts, and essential oils (adapted from Ref. <sup>5</sup>)

Acetic acid
Acetophenone
Acetovanillone (4-hydroxy-3-methoxyacetophenone)
$\alpha$ -Amorphene
Amyrin
Aristolene
Benzaldehyde
Benzoic acid (1.5%-11%)
Benzyl alcohol (1%-2%)
Benzyl benzoate (up to 30%)
Benzyl cinnamate (up to 40%)
Benzyl <i>p</i> -coumarate (benzyl- <i>trans</i> -4-hydroxycinnamate)
Benzyl ferulate
Benzyl formate
Benzyl isoferulate ( <i>cis</i> and <i>trans</i> ) (0.2%)
Benzyl vanillate (benzyl 4-hydroxy-3-methoxybenzoate)
<i>cis</i> - $\alpha$ -Bisabolene, $\beta$ -bisabolene and <i>cis</i> - $\gamma$ -bisabolene and <i>trans</i> - $\gamma$ -bisabolene
$\beta$ -Caryophyllene
1,8-Cineole
<i>cis</i> -Cinnamic acid and <i>trans</i> -cinnamic acid (3%-30%)
Cinnamyl alcohol (0.4%)
Cinnamyl cinnamate (0.5%)
Coniferyl alcohol (0.2%)
<i>cis</i> -Coniferyl benzoate and <i>trans</i> -coniferyl benzoate (up to 1.5% in fresh MP)
Coniferyl cinnamate
$\alpha$ -Copaene
$\alpha$ -Curcumene
Cycloisositivene
<i>p</i> - $\beta$ -Cymene and <i>trans</i> - $\beta$ -cymene
Docosanoic acid
Dodecanoic acid
Eicosanoic acid (arachidic acid)
Ethylbenzene
Ethyl benzoate
Ethyl cinnamate
Ethylhexanoic acid (tentatively identified)
Eugenol (0.2% in fraction BP3)
$\alpha$ -Farnesene and $\beta$ -farnesene
Farnesol (traces)
Ferulic acid (0.1%-0.4%)
Formic acid
Geranyl acetone
Guaiacol
Heptadecanoic acid (margaric acid)

**TABLE 1** (Continued)

Hexacosanoic acid (cerotic acid)
1-Hexacosanol
Hexadecanoic acid (palmitic acid)
Hydroconiferyl benzoate
Hydroconiferyl cinnamate
Hydroxycinnamic acid
Isoeugenol (0.85% in fraction BP3)
Isoferulic acid (traces)
Lactic acid (2-hydroxypropanoic acid)
Limonene
Methoxyeugenol
Methyl benzoate
Methyl cinnamate
Methyl vanillyl ketone
$\alpha$ -Muuroleone
Naphthalene
Nerolidol (2%-7%)
allo- $\beta$ -Ocimene, <i>cis</i> - $\beta$ -ocimene and <i>trans</i> - $\beta$ -ocimene
1-Octacosanol
Patchoulene
$\alpha$ -Phellandrene and $\beta$ -phellandrene
1-Phenylethanol ( $\alpha$ -methylbenzyl alcohol)
3-Phenylpropanol
$\alpha$ -Pinene and $\beta$ -pinene
$\beta$ -Sesquiphellandrene
Stearic acid (octadecanoic acid)
Styrene
$\alpha$ -Terpinene and $\gamma$ -terpinene
4-Terpineol (terpinen-4-ol)
$\alpha$ -Terpineol
1-Tetracosanol (lignoceryl alcohol)
Tetradecanoic acid (myristic acid)
1-Undecanol
Vanillic acid (4-hydroxy-3-methoxybenzoic acid)
Vanillin (0.2%-1.3%)
<i>p</i> -Vinylguaicol

Abbreviation: BP3, balsam of peru fraction 3; MP, *myroxylon pereirae* resin.

### 3 | CONTACT ALLERGY

Contact allergy to MP has been seen slightly more often in women in most studies<sup>26-28</sup>; in some investigations, the percentages of men reacting to MP were somewhat (although not significantly) higher.<sup>29,30</sup>

In almost all studies, MP allergy occurred significantly more often in the older (>40 years) age groups.<sup>26,27,29-31</sup> In a large Information Network of Departments of Dermatology (IVDK) study, risk quantified by the prevalence ratio rose with increasing age vs reference (age

1-36 years) from 1.87 (age 37-50 years) and 2.79 (age 51-64 years) to 3.32 (age 65-99 years).<sup>26</sup>

### 3.1 | Frequency of sensitization

#### 3.1.1 | General population

In a 2018 meta-analysis of 12 studies covering 8002 patch tested individuals from the general population, the pooled prevalence of sensitization to MP was 1.8%.<sup>32</sup> Estimates of the 10-year prevalence of contact allergy to MP in the general population of Denmark based on the clinical epidemiology drug-utilization research method in 2006 ranged from 0.57% to 0.77%.<sup>33</sup> In a similar study from Germany, the estimated prevalence in the general population in the period 1992 to 2000 ranged from 1.3% to 3.0%.<sup>34</sup>

#### 3.1.2 | Patch testing in consecutive patients suspected of having contact dermatitis (routine testing)

As MP is present in most, if not all, baseline series used for routine screening testing worldwide, data on testing MP in consecutive patients are abundant. The results of nearly 55 such published investigations back to 2000 were shown in detail in 2019<sup>5</sup> and are summarized here. MP is nearly always tested at 25% pet. The test material from Chemotechnique contains 5% sorbitan sesquioleate. The TRUE Test system appears to be less sensitive for detecting sensitivity to MP than the petrolatum-based chamber systems.<sup>35,36</sup>

In 14 studies from the United States, 10 of which were performed by the North American Contact Dermatitis Group (NACDG), frequencies of sensitization have ranged from 6.6% to 13.7%.<sup>5,37</sup> Generally speaking, the rates appear to have decreased somewhat in the last decade, ranging in all NACDG studies between 7% and 8%. In Europe, 12 multinational multicentre studies have been performed by the European Surveillance System on Contact Allergy network, the IVDK in Germany, Switzerland, and Austria, the European Environmental and Contact Dermatitis Research Group, and other parties. The frequencies of sensitization have ranged in a very narrow band of 5.3% to 6.4% in most investigations<sup>36,38-43</sup>, but were higher (6.8%-9.2%) in the IVDK studies.<sup>5,26,44</sup> Often, there was significant variability in the results per centre or country: 3.6% to 12.8%,<sup>36</sup> 1.6% to 10.6%,<sup>38</sup> 1.4% to 14.6%,<sup>39</sup> 2.3% to 12.9%,<sup>40</sup> and 2.8% to 10.9%.<sup>41</sup>

Concerning other European countries, four Danish studies with overlapping study periods and populations found frequencies of sensitization ranging from 2.8% to 4.4%.<sup>5,45</sup> In four investigations from the United Kingdom, frequencies of positive patch test reactions ranged from 2.9% to 6.4%, with lower rates in recent periods.<sup>5,46,47</sup> In Spain, positivity rates were 2.4%, 6.4%, and 5.8%.<sup>31,48,49</sup> In Sweden, 4.8% to 6.5% of routine patients reacted to MP.<sup>27,30,50</sup> Other European countries have also presented their patch test results with MP: The Netherlands, 2.8% (the low frequency probably resulting from the use of TRUE Test); Finland, 6.2%; Belgium, 6.1%; Switzerland, 7.8%; and the Czech Republic, 7.3%.<sup>5</sup>

Data on the frequencies of sensitization to MP are available from Thailand, Singapore, China, Australia, Iran, Israel, and Turkey. The rates ranged from 2.1% to 8.9%, with low rates in Turkey and Iran, and the highest rate in Australia.<sup>51</sup>

#### 3.1.3 | Relevance and causative products

In the studies performed by the NACDG, generally 30% to 35% of the positive patch test reactions were scored as having "definite" or "probable" relevance, but very few reactions were considered to be definitely relevant.<sup>5,37</sup> Only six of the remaining 41 studies provided relevance data.<sup>5,45,48,49,51</sup> The percentages of positive reactions considered to be relevant ranged from 21% to 75%. In just one of the 55 investigations were products containing MP that caused dermatitis mentioned.<sup>49</sup> In this study from Spain, performed in the period 2002 to 2004, among 50 MP-allergic patients seen in one clinic, 32 reactions (64%) were considered to be relevant. In 19 patients, the culprit products were topical pharmaceuticals, and in 13 patients dermatitis had (apparently) been caused by cosmetics containing MP.<sup>49</sup>

#### 3.1.4 | Patch testing in groups of selected patients

Many investigators have presented their results of patch testing with MP (and usually many other allergens) in groups of selected patients, for example, physical therapists, patients with eyelid/periorbital dermatitis, patients with allergic contact cheilitis, patients with stasis dermatitis/leg ulcers, patients suspected of having cosmetic intolerance or fragrance allergy, and patients with hand dermatitis. Most studies have been retrospective. These studies can be interesting when unexpected elevated frequencies are observed, which may indicate exposure to unknown sources of MP. Unfortunately, in by far most of the studies, there were no data on the frequency in a control group of patients routinely tested or other adequate controls. In addition, as MP is an indicator of fragrance allergy, any selection towards groups with an elevated risk of fragrance sensitization will inevitably lead to increased percentages of positive reactions to MP, not necessarily as an expression of (increased) exposure to the material itself. Other limitations of studies testing selected groups of patients are that data on relevance were provided in no more than 30% of the investigations, and that the culprit products were hardly ever mentioned.

In eight studies testing patients with stasis dermatitis and/or leg ulcers between 2002 and 2016, frequencies of sensitization to MP ranged from 13.6% to 50%; most found 30% to 40% positive reactions.<sup>52-59</sup> It is clear that, in all studies, the frequencies of sensitization to MP were higher than in routinely tested patients<sup>53,55,58,59</sup> or than expected. Relevance was mentioned in one study only: "definite" 0%, "probable" 6%.<sup>52</sup> Causative products were never mentioned. However, in a 2005 to 2008 study from France, where very high rates of sensitization to MP have been observed in the past in patients with stasis dermatitis and/or leg ulcers,<sup>57</sup> it was mentioned that, at that time, wound dressings with MP were still being used in France for leg ulcers.<sup>54</sup> In IVDK studies, the localization "feet/legs" was a risk factor

for a positive patch test reaction to MP, with a prevalence ratio of 1.45.<sup>26</sup>

In six studies in groups of patients with cosmetic allergy (allergic contact cheilitis, patients known to be allergic to cosmetics or fragrances, and patients with previous positive patch test reactions to deodorants, perfumes, eau de toilette, aftershave, bath or shower products, or skin creams), frequencies of sensitization to MP ranged from 14% to 45%, and were mostly between 17% and 24%.<sup>60–65</sup> These high frequencies are hardly surprising, considering the selection criteria. Relevance in three studies addressing this issue was 100%<sup>62,63,65</sup> (the latter selected on the basis of relevant reactions), but causative products were not mentioned.

In six studies in groups of patients suspected of having cosmetic or fragrance allergy,<sup>66–71</sup> frequencies of sensitization ranged from 9.4% to 19.6%. Relevance was mentioned in one study only (95%), but this investigation had certain weaknesses.<sup>66</sup> There was a control group in only one study: the frequency of sensitization in the group suspected of having cosmetic/fragrance allergy (7.9%) was significantly higher than in a control group undergoing routine testing.<sup>70</sup>

In seven studies in which patients with eyelid dermatitis or periorbital dermatitis were patch tested with MP, frequencies of sensitization ranged from 1.7% to 17%, but in five of the seven studies, the frequency was <7%.<sup>72–78</sup> In three investigations in which relevance was addressed, rates of relevant reactions were 43%,<sup>77</sup> 58%,<sup>78</sup> and 75%,<sup>74</sup> but the culprit products were not mentioned. In four studies with a control group, the frequency of sensitization to MP was significantly lower than in routine testing.<sup>73–75,78</sup>

In hairdressers, the prevalence of sensitization to MP in most studies was not or only slightly elevated,<sup>79–83</sup> which also applies to healthcare professionals, including nurses.<sup>84–86</sup> However, adequate control groups are largely lacking. Other indications for patch testing with MP have included individuals suspected of having photodermatoses, children, physical therapists, and patients with pure allergic hand dermatitis, with poikiloderma of Civatte, and with facial allergic contact dermatitis; convincingly elevated rates of sensitization to MP were not observed.<sup>5</sup>

## 3.2 | Case reports and case series

### 3.2.1 | Pharmaceuticals

In the past, MP was widely used in topical pharmaceutical preparations, and these were important sources of sensitization. In Hjorth's investigations, published in his 1961 PhD Thesis,<sup>2</sup> for example, of 126 balsam of Peru-allergic patients who had reported having used preparations containing MP, 111 (88%) had used the official 10% pet. Balsamum Peruvianum of the Danish pharmacopoeia, approximately half of them for burns. Forty-eight of 230 MP-positive individuals had been referred because of allergic contact dermatitis caused by MP preparations. Most reactions were caused by pure MP or MP in topical pharmaceutical preparations, including ointments, gauzes, and suppositories.<sup>2</sup> Eight patients from France in the mid-1970s had allergic contact cheilitis caused by MP in "Dermophil Indien," a

pharmaceutical lip stick.<sup>87</sup> Quite remarkably, this product is still available, and even now contains MP.<sup>88</sup>

In the period 1990 to 2016, in a clinic in Belgium, 125 patients were investigated for allergic contact dermatitis caused by a medicinal herbal preparation.<sup>13</sup> In 30 (24%) patients, MP was the active principle in these preparations. Currently, these preparations are only rarely used in Belgium (although some preparations still contain MP<sup>88</sup>), and the majority of positive reactions were observed before the year 2000.<sup>13</sup> In the period 1978 to 2008, in the same clinic, 16 patients had allergic contact dermatitis caused by MP in topical pharmaceutical preparations, 13 for wound healing, two for the treatment of haemorrhoids, and one antiseptic/disinfectant.<sup>89</sup> There is very likely overlap with the data from Ref. <sup>13</sup>

Two patients presented with cheilitis and perioral dermatitis. Patch testing showed positive reactions to MP and to an ointment used as a lip balm, and for minor burns, cuts, nappy rash, sunburn, rash, and scalds. MP was not listed as an ingredient in this ointment, but the manufacturer confirmed that a small amount of MP was present in the product.<sup>90</sup> A man presented with a 12-week history of non-healing perianal erosions. He was prescribed a "healing spray" containing trypsin, MP, and castor oil, and the sores progressed to ulcerations. Use of the spray was discontinued, and the patient was patch tested; this showed positive reactions to MP, eugenol, and the spray. During the patch test, the perianal area became indurated.<sup>91</sup> A woman developed severe weeping dermatitis of the face after the application of an MP-containing ointment. This was followed by dissemination to the legs, where the ointment had not been applied. The eruption on the legs resembled vasculitis, with diffuse redness and numerous partly purpuric papules and some slightly haemorrhagic bullae. Patch testing showed the patient to be allergic to MP, fragrance mix (FM) I, colophonium, wood tars, eugenol, isoeugenol, oil of cloves (main ingredient: eugenol), and lavender oil. Although the authors suggested that systemic spread of the allergen was plausible, they did not, quite curiously, consider the possibility of systemic allergic dermatitis resulting from the ingestion of food or drinks.<sup>92</sup> One other patient apparently also had purpuric vasculitis-like lesions caused by allergy to MP.<sup>93</sup> A veterinarian had occupational allergic contact dermatitis of the hands caused by MP-containing ointments that he used for treating animals.<sup>11</sup>

### 3.2.2 | Cosmetics

MP was stated to be the (or an) allergen in 71 patients in a group of 603 individuals (11.8%) suffering from cosmetic dermatitis, seen in the period 2010 to 2015 in Leuven, Belgium.<sup>94</sup> In the period 1996 to 2013, in a tertiary referral centre in Valencia, Spain, 628 individuals had allergic contact dermatitis caused by cosmetics. In this group, MP was stated to be the responsible allergen in 17 (2.7%) cases (Ref. <sup>95</sup>overlap with Ref. <sup>96</sup>). In the period 2000 to 2007, 202 patients with allergic contact dermatitis caused by cosmetics were seen in the same clinic in Valencia, Spain. In this group, MP was the allergen in four (2%) individuals, resulting from its presence in moisturizing cream



( $n = 2$ ), deodorant ( $n = 1$ ), and perfume ( $n = 1$ ) (Ref. <sup>96</sup> overlap with Ref. <sup>95</sup>).

In Belgium, between 1985 and 1990, 3970 patients with dermatitis were patch tested. Four hundred and sixty-two of these reacted positively to patch tests with “cosmetic allergens.” The reactions were considered to be relevant in 68%, probably relevant in 25%, and doubtfully relevant in 7%. In the list of “most common allergens”, MP had rank number 2, with 114 reactions (24.7% of the positively tested patients).<sup>97</sup> In Belgium, in the years before 1986, of 5202 consecutive patients with dermatitis who were patch tested, 156 were diagnosed with pure cosmetic allergy. MP was the “dermatitic ingredient” in 52 (33%) patients (frequency in the entire group: 7%).<sup>98</sup>

In the late 1980s, MP was present in several popular over-the-counter nappy products in the United States, and may have caused allergic contact dermatitis in children or resulted in fragrance sensitization.<sup>99</sup> Balsam of Peru was responsible for three of 399 cases of cosmetic allergy for which the causal allergen was identified in a study of the NACDG in 1977 to 1983.<sup>100</sup>

Hjorth, in 1961, mentioned perfumed soaps, perfumes and fragranced cosmetics (including a toothpaste containing oil of cinnamon and a hair lacquer containing benzoin) as causative products in a number of patients with allergy to MP, but the presence of MP in those products was never verified. However, some patients did react to one of more fragrance chemicals that are also present in MP.<sup>2</sup>

The author has not been able to find a single case report of proven cosmetic allergy caused by MP (contact dermatitis caused by cosmetic products, positive patch test reaction to MP, a positive patch test, repeat open application test or use test result with the product, the presence of MP in a cosmetic verified, and resolution or improvement of dermatitis after cessation of use of the product).

### 3.2.3 | Foods and drinks

In several case histories of MP-allergic patients, the development of dermatitis or exacerbations thereof,<sup>2,11,101-105</sup> ulcerations of the tongue<sup>106</sup> or glossodynia<sup>11</sup> have been ascribed to foods and drinks such as cola, vermouth, vanilla, chocolate, cinnamon cakes, wine gums, liqorice, marzipan, caramels, cream toffees, ice cream, and other sweets/candies. In some individuals, avoidance of these products resulted in improvement or healing of the symptoms<sup>2,104,107</sup>; in others, the dermatitis resolved or improved after use of a MP-restrictive diet,<sup>105,106,108-110</sup> sometimes combined with other measures, such as the avoidance of fragranced products.<sup>106,108</sup> In a number of these patients, oral administration of MP resulted in exacerbation of dermatitis.<sup>104,105,110</sup>

### 3.2.4 | Miscellaneous products

Twenty-five case reports of contact allergy to MP mentioning the patients' sex, age, profession, site of skin lesions, co-reactions, reactions to constituents, individual habits, possible aetiologies and comments/remarks were reported in the mid-1990s in Germany.<sup>11</sup> The most important possible aetiologies were plastics, consumption of

sweets, smoking (in those days, MP and various of its ingredients were added to tobacco in the manufacture of cigarettes), and wound healing/herbal ointments.<sup>11</sup> Plastics were considered to be relevant in patients reacting to resorcinol monobenzoate, which is an ultraviolet stabilizer in cellulose acetate and other plastic materials. This chemical has not been identified in MP, but frequently reacts, for unknown reasons, in MP-positive individuals (cross-reaction with coniferyl benzoate?). However, plastic as a cause of allergic contact dermatitis in MP-allergic patients and resorcinol monobenzoate was not well substantiated, as the chemical has never been shown to be present in MP, and its presence in the plastic was never ascertained by the author.<sup>11</sup>

A factory worker preparing copper mirrors for carbon anhydride lasers developed dermatitis of the fingers of his right hand. He had positive patch test reactions to MP and a cutting fluid. The manufacturer did not provide data on the composition of the fluid, but other MP-allergic patients also reacted to the product. In addition, neither the patient nor other MP-allergic individuals had positive test reactions to the non-perfumed variety of the same brand of cutting fluid.<sup>111</sup> Although this does not prove that MP was present in the cutting fluid, this possibility cannot be excluded. One or more separate ingredients of MP may also have caused the reaction in the cutting fluid.

## 4 | THE SENSITIZERS IN MP

Since Hjorth's classic study on balsam of Peru in 1961,<sup>2</sup> in which he found that 80% of his MP-allergic patients reacted to coniferyl benzoate, this has been considered to be the most important allergen in the product. However, coniferyl benzoate was first identified in MP in 1995, 34 years later!<sup>6</sup> It was the strongest sensitizer of all MP ingredients tested in guinea-pigs.<sup>2,6</sup> Moreover, it was said that it can only be found when fresh samples of MP are investigated, as it is very unstable and degrades in MP and syringes very quickly.<sup>6</sup> In several studies, patients known to be allergic to MP have been tested with selected ingredients.<sup>2,11,112-114</sup> The results are shown in Table 2.

The results have varied widely. There were differences in the methodology of patch testing, the size of the populations tested, the number and nature of ingredients tested, the test concentrations, and, sometimes, the vehicles used; and, of course, different samples of MP were used with—most likely—different compositions. Therefore, reliably identifying the main sensitizers in MP on the basis of the available data is not possible.

The highest percentages of positive reactions were caused by coniferyl benzoate, isoeugenol, eugenol, cinnamyl alcohol, cinnamic acid, and cinnamyl cinnamate. Coniferyl benzoate is a potent sensitizer, and MP may contain up to 30% cinnamic acid. However, the other substances appear to be present in MP in low concentrations. Whether these are high enough in MP to induce contact allergy and/or elicit allergic contact dermatitis in previously sensitized individuals has not been investigated. There may be cross-reactivity between eugenol and isoeugenol, and between cinnamic acid, cinnamyl alcohol, and cinnamyl cinnamate, thereby enhancing the sensitizing/eliciting

**TABLE 2** Results of patch tests with components of *Myroxylon pereirae* resin (MP) in allergic patients (adapted from Ref. 5)

Compound	No. of studies	No. of patients	Test concentrations	Percentage positive (range)	References
Coniferyl benzoate <sup>a</sup>	2	184	0.5%, 1% and 2% pet.	28-81	2,11
Isoeugenol	2	235	2% pet.; 5% pet.	27-62	2,11
Eugenol	4	383	2% and 5% pet.; unknown	0-62	2,11,113,114
Cinnamyl alcohol	4	349	5% and 10% pet.; unknown	0-37	2,11,113,114
Cinnamic acid	4	387	5% pet.; unknown	13-32	2,11,112,113
Cinnamyl cinnamate	2	114	5% pet.	20-25	11,114
Cinnamal <sup>b</sup>	2	213	2% pet.; unknown	10-21	2,113
Benzoic acid	2	241	5% pet.	8-20	2,11
Benzyl alcohol	2	197	5% pet.; 10% eth.	8-20	2,11
Benzyl cinnamate	4	366	5% pet.; unknown	3-19	2,11,113,114
Vanillin	4	420	5% and 10% pet.; pure	0-17	2,11,113,114
Resorcinol monobenzoate <sup>c</sup>	1	102	2% pet.	16	11
Coniferyl alcohol	1	102	1% pet.	14	12
Benzyl benzoate	4	371	5% pet.; unknown	0-12	2,11,113,114
Benzaldehyde	1	100	5% pet.	10	2
Nerolidol	2	153	1% pet.; 3% olive oil	3-6	2,11
Farnesol	2	155	5% pet.; 50% olive oil	2-4	2,11
Methyl cinnamate	3	259	10% and 25% pet.; unknown	0-4	11,112,113
Benzyl isoferulate	1	102	1% pet.	2	11
Isoferulic acid	1	102	5% pet.	1	11
Ferulic acid	1	102	5% pet.	0	11

<sup>a</sup>Coniferyl benzoate is an unstable chemical, and is swiftly degraded in MP and in commercial test syringes.

<sup>b</sup>Not a constituent of MP; may be a sensitizer after conversion in the skin of cinnamyl alcohol to cinnamal.

<sup>c</sup>Resorcinol monobenzoate has not been identified in MP; however, patients sensitized to resorcinol monobenzoate for unknown reasons almost invariably react to MP<sup>11,115,116</sup>; conversely, only 0% to 16% of patients sensitized to MP co-react to resorcinol monobenzoate<sup>11,117</sup>.

potential. Alternatively, some patients may well have become sensitized to these substances because of their presence in other products. In other words, a reaction to an ingredient in these studies does not necessarily mean that the patient had become sensitized to it from contact with MP. However, the relationship with some ingredients is clear. In one study, the odds ratios of a reaction to MP were 51 in patients reacting to its ingredient eugenol, 25 in patients reacting to isoeugenol, and 13 in patients reacting to cinnamyl alcohol.<sup>20</sup> In two other investigations, 70%<sup>118</sup> and 73%<sup>47</sup> of patients reacting to eugenol, 36%<sup>47</sup> and 63%<sup>118</sup> of patients reacting to isoeugenol and 24%<sup>47</sup> and 42%<sup>118</sup> of patients reacting to cinnamyl alcohol co-reacted to MP. Moreover, of seven patients reacting to benzyl alcohol, which is also present in MP, four (57%) co-reacted to MP.<sup>114</sup>

It seems highly likely that at least a number of these patients, possibly most, had previously become sensitized to these fragrances from sources other than MP, and that the concentration of the fragrance in the 25% pet. patch test material was high enough, possibly together with the effect of other sensitizers, cross-reactors, and irritants, to elicit a positive MP patch test reaction. Similar phenomena are well known with fragrances and essential oils, whereby fragrance-allergic individuals have positive patch test reactions to essential oils containing these fragrances (eg, geraniol and rose and geranium essential oils, and limonene and tea tree oil), even when previous contact with the oils is unlikely.<sup>5</sup>

## 5 | CROSS-REACTIONS, PSEUDO-CROSS-REACTIONS, AND CO-REACTIONS

It is well known that fragrance-allergic patients often react to several or even many fragrances, indicators (FM I, FM II, MP, and colophonium), essential oils, and fragranced products (polysensitization<sup>119</sup>). Possible explanations are: (a) cross-reactivity (sensitization to fragrance A, inducing contact allergy to structurally related fragrance B, with which the patient had never had contact; almost impossible to prove); (b) pseudo-cross-reactions (the patch test substances contain the same hapten; also termed "false cross-reactivity"<sup>26</sup>); (c) metabolization or oxidation of one fragrance into another (eg, cinnamyl alcohol into cinnamal, and geraniol into geranial and neral); (d) concomitant sensitization from their presence in the same product (coupled exposure); and (e) independent sensitization over time in different products.

For co-reactivity (also termed coupled reactivity<sup>26</sup>) of indicators and their ingredients, pseudo-cross-reactivity is a very plausible explanation, and this also applies to many cases of positive patch test reactions to individual fragrances and essential oils containing them. Co-reactivity of individual fragrance chemicals may mostly be the result of concomitant or independent sensitization, facilitated by the extremely widespread use of perfumes and perfumed products

containing many different fragrance chemicals. One final explanation for co-reactivity between MP, FM I and its ingredients is not fragrance sensitization, but contact allergy to sorbitan sesquioleate, which may be present in all of these patch test materials (depending on the supplier) for proper emulsification. If sorbitan sesquioleate is not routinely tested, this possibility goes unnoticed and the patients may be advised improperly.

## 5.1 | Ingredients of MP

Co-reactivity of many fragrant chemicals with MP can be expected, when these are present in MP in concentrations adequate for elicitation of a positive patch test reaction (pseudo-cross-reactions). For eugenol, isoeugenol, cinnamyl alcohol, and benzyl alcohol, this has been discussed in the section "The sensitizers in MP" above. Elevated rates of co-reactivity between MP and fragrances are not specific for ingredients of MP. Geraniol-allergic patients, for example, had an odds ratio of 13.6 for reacting to MP in one study,<sup>20</sup> although MP does not contain geraniol or its aldehydes geraniol and neral formed by oxidation. The chemicals that have been identified in MP are summarized in Table 1.

## 5.2 | Fragrance mix I

A high degree of co-reactivity between MP and FM I and vice versa has been observed in numerous studies. In groups of MP-allergic patients, 18%,<sup>49</sup> 25%,<sup>120</sup> 33%,<sup>121</sup> 36%,<sup>48</sup> 38%,<sup>122</sup> 39%,<sup>123</sup> 45%,<sup>124</sup> 48%,<sup>11</sup> 51%,<sup>125</sup> and 59%<sup>126</sup> co-reacted to FM I. Conversely, of patients reacting to FM I, 9%,<sup>120</sup> 15%,<sup>121</sup> 22%,<sup>12</sup> 27%,<sup>127</sup> 33%,<sup>125,126</sup> 34%,<sup>128</sup> 31% to 39%,<sup>129</sup> 44%,<sup>123</sup> 52%<sup>48</sup> and 59%<sup>126,130</sup> co-reacted to MP.

These two substances share common components, that is, eugenol, isoeugenol, and cinnamyl alcohol. FM I also contains cinnamal; MP does not, but cinnamyl alcohol in MP may be converted in the skin into cinnamal, which then acts as a sensitizer or reacts in cinnamal-allergic individuals. Indeed, cinnamal is patch test-positive in 10% to 20% of MP-allergic patients,<sup>2,113</sup> and, in cinnamal-allergic individuals, MP allergy is overrepresented.<sup>20,47</sup> In one study, even 14 of 27 (52%) cinnamal-allergic patients also reacted to MP.<sup>123</sup> MP (from Chemotechnique Diagnostics) and FM I both contain the emulsifier sorbitan sesquioleate, which may be an occasional cause of contact allergy and co-reactivity between the two patch test materials.

## 5.3 | Propolis

Chemicals present in both propolis and MP include benzoic acid, benzyl alcohol, benzyl benzoate, benzyl caffeate, benzyl cinnamate, benzyl ferulate, benzyl isoferulate, caffeic acid, cinnamic acid, cinnamyl alcohol, coniferyl benzoate, farnesol, nerolidol, and vanillin.<sup>131</sup> Therefore, a certain degree of co-reactivity based on pseudo-cross-reactions may be anticipated. Indeed, 19 of 21 (90%)<sup>114</sup> and six of seven (86%)<sup>132</sup> propolis-allergic patients co-reacted to MP 25% pet. Conversely,

of 11 MP-positive patients who had never come into contact with propolis, five (45%) also reacted to propolis.<sup>114</sup> In a large German study, however, of 102 MP-allergic patients, only nine (9%) co-reacted to propolis.<sup>11</sup> This asymmetrical co-reactivity pattern suggests that most of the sensitizers in propolis are also present in MP, but that some sensitizers in MP are not present in propolis or are present in concentrations too low to elicit a positive patch test reaction. Obviously, both are botanical products, and the composition of the samples used by the various investigators may have differed considerably, thereby influencing the results.

## 5.4 | Essential oils

Of 31 MP-allergic patients, 18 (58%) had positive patch test reactions to one (n = 12), two (n = 3), five (n = 1), six (n = 1) or nine (n = 1) of 35 essential oils. Most positive reactions were observed to cassia oil (high concentration of cinnamal) and to clove oil (high concentration of eugenol).<sup>133</sup>

## 5.5 | Other resins and balsams

Co-reactivity to other resins and balsams in MP-allergic individuals was investigated by Hjorth in 1961<sup>2</sup> and by Hausen et al in 1995.<sup>6</sup> In MP-allergic patients, frequent co-reactions were observed to balsam of Tolu (INCI name: *Myroxylon balsamum* resin) (47%), styrax/storax (INCI name: *Liquidambar orientalis* resin) (43%), Siam benzoin (INCI name: *Styrax tonkinensis* resin; contains 75% coniferyl benzoate and 10% benzoic acid) (80%), Sumatra benzoin (INCI name: *Styrax benzoin* gum) (43%), and compound tincture of benzoin U.S.P (contains styrax, benzoin, and balsam of Tolu) (90%).<sup>2,6</sup> In a group of 21 patients allergic to tincture of benzoin, 13 (62%) co-reacted to MP.<sup>13</sup> These products all have (many) ingredients in common with MP.

A number of resins and balsams were tested 10% in ethanol in a small series of MP-allergic patients. Six of 11 (55%) reacted to opoponax (*Commiphora erythrea glabrescens* gum), seven of 13 (54%) to Copaiba balsam (*Copaifera reticulata* balsam), and three to galbanum (*Ferula galbaniflua* gum).<sup>2</sup> In addition, three of 14 MP-allergic patients (21%) reacted to an extract of poplar buds (the source material for propolis, which often co-reacts with MP and in which caffeates are the main sensitizers), seven of 20 (35%) to ginger resinoid 10% pet., and all five tested with Tiger Balm.<sup>2</sup>

## 5.6 | Other co-reactions

Positive patch test reactions to MP (and to FM I) are very frequently observed in patients who are photoallergic to ketoprofen; the mechanism behind this has not been elucidated.<sup>134,135</sup> Patients sensitized to resorcinol monobenzoate almost<sup>136</sup> invariably react to MP<sup>11,115,116</sup>; conversely, only 0% to 16% of patients sensitized to MP co-react to resorcinol monobenzoate.<sup>11,117</sup> Resorcinol monobenzoate has not been identified in MP, and the mechanism behind the co-reactivity is unknown.



Of 11 patients with contact allergy to oranges (peel), five (45%) co-reacted to MP. Eight patients known to be sensitive to MP were patch tested with an ether extract of orange peel 10% pet., and five (63%) had strong reactions to the extract.<sup>22</sup> Of 73 patients sensitive to MP, 34 (47%) co-reacted to vanilla. This is not entirely attributable to vanillin being present in both products, as vanilla has only a low concentration of vanillin, and reactions to vanillin 10% pet. and vanillin pure were less frequent than reactions to vanilla.<sup>2</sup> A statistically significant overrepresentation has been found of simultaneous patch test reactions to MP and phenol-formaldehyde resins (PFRs).<sup>125</sup> Approximately 20% of those allergic to MP co-react to PFRs. It was suggested that this was attributable to the presence of low-molecular-weight phenols in both substances.<sup>137</sup>

## 6 | MP AS AN INDICATOR OF FRAGRANCE ALLERGY

MP has been used as a “marker” (or “indicator”) of fragrance sensitivity in the European baseline series for patch testing since it was discovered in the 1960s that half of the patients with positive reactions to MP were also allergic to one or more toilet soap perfumes and vice versa.<sup>2,3</sup> MP was the most important marker until FM I was introduced in the late 1970s; in 2008, FM II and its separate fragrance ingredient hydroxyisohexyl 3-cyclohexene carboxaldehyde (Lyrall) were added to the baseline series.<sup>138</sup> Currently, in most patients reacting to MP, fragrance allergy appears to be already detected by other fragrance indicators, notably FM I, and it has been shown that the composition of FM I is a good reflection of actual exposure to fragrances.<sup>121,139</sup> Therefore, some authors have suggested that MP may be of limited value in detecting cases of clinically relevant fragrance allergy, and that consideration should be given to the replacement of MP with more well-defined markers of fragrance allergy in order to detect cases not identified by FM I.<sup>9,13,114,120,140,141</sup> Nevertheless, now, 20 years after these studies, MP is still part of most (if not all) baseline series, and, when fragrance markers have been discussed in recent literature, MP has always been mentioned. Indeed, it was recently concluded that “Exposure to *M. pereirae*, or to some of the single constituents, is apparently frequent, so this ‘historical’ screening agent is still important for detecting fragrance sensitivity.”<sup>20</sup>

Contact allergy to MP 25% in the baseline series occurs frequently; in most countries, rates of positive reactions are 4% to 8% or higher in routine testing (see section “Patch testing in consecutive patients suspected of having contact dermatitis [routine testing].”) Many patients with positive reactions to MP (41%–72%) do not react to FM I (see section “Fragrance mix” above). In addition, there can be no doubt that MP is indeed a marker of fragrance allergy. In studies in which patients were patch tested with MP and with other fragrances such as individual fragrance chemicals, essential oils,<sup>142</sup> perfumes from cosmetic products, or fine fragrances, 24% to 74% of the patients reacting to MP also had positive patch test reactions to one or more of the fragrance test substances: 24% and 25%,<sup>143</sup> 29% and 35%,<sup>140</sup> 41%,<sup>144</sup> 42%,<sup>121</sup> 48%,<sup>48</sup> and 74%.<sup>47</sup> Conversely, in the

groups of patients reacting to one or more fragrances, fine fragrances, or perfumes, only 15%,<sup>141</sup> 22%,<sup>121</sup> and 10% and 38%<sup>140</sup> co-reacted to MP. Thus, there appears to be an asymmetrical co-reactivity pattern; the percentages of fragrance-positive individuals reacting to MP are low, whereas the percentage of MP-allergic individuals reacting to fragrances is high. A possible explanation—on the assumption that co-reactivity is caused by common ingredients—is that strong allergies induce positive patch test reactions to both MP and the fragrances, but weaker sensitivity only manifests as reactions to the fragrances, and not to MP, because of (too) low concentrations of the latter. Another possibility is that a large proportion of reactions to MP are caused by (unknown) components that are not present in the perfumes/essential oils/common fragrances tested (hence low co-reactivity to MP in fragrance-allergic individuals), but that allergy to these components does point at sensitivity to other fragrances (hence high co-reactivity to other fragrances in MP-allergic patients). Coniferyl benzoate might qualify for this, as this chemical has been an important sensitizer in MP in some studies, but is not used in fragrances.<sup>145</sup>

In all investigations, the percentages of patients reacting to FM I who also reacted to specific fragrances/perfumes and fine fragrance/essential oils, and the reverse situation, the percentage of patients allergic to fragrances who also reacted to FM I, were higher or far higher than the corresponding percentages for MP (ie, FM I is the more sensitive marker). In the case of the perfumes and fine fragrances, this can probably be attributed to the fact that all of these products proved to contain at least one and most often more than one of the ingredients of FM I.<sup>121,140,141,143</sup> In the studies in which a fragrance series was tested, it can be explained by the fact that the series always contained all ingredients of FM I.<sup>47,143,144</sup> It can be concluded that, although FM I is clearly the more sensitive marker for fragrance allergy, MP is also a—slightly ill-defined<sup>26</sup>—“natural fragrance mix” acting as a fragrance marker.

### 6.1 | Added value of testing with MP: number of cases identified

The added value of testing with MP in the baseline series can be debated, if fragrance sensitization is indeed, in most cases, already picked up by a positive FM I reaction. In other words, how many cases of fragrance sensitization does a positive MP patch test reaction identify that are not already shown by FM I positivity or one of the other indicators (colophonium and FM II)? Only few data are available to help in answering this question, and they are limited to FM I.

In a study from Denmark, 335 female patients were patch tested with 10 popular women’s perfumes, FM I, and MP. There were 23 reactions to one or more commercial perfumes. Twenty of them co-reacted to FM I, and five to MP; these five also reacted to FM I. No additional cases were detected by MP.<sup>121</sup> In another study from the same investigators, of 33 patients reacting to one or two fine fragrances, 20 co-reacted to FM I and five to MP. All MP-responsive individuals were also allergic to FM I.<sup>141</sup> In a third study from this group, of 21 patients reacting to one or more fragrances used in rinse-

off products, 11 (52%) co-reacted to FM I and two (10%) to MP (TRUE Test, lower sensitivity for detecting FM I and MP allergy). In the same study, of 16 patients reacting to one or more fragrances used in leave-on products, 13 (81%) co-reacted to FM I and six (38%) to MP. When testing with MP was performed, only one case of fragrance allergy was identified that was not already detected by FM I.<sup>140</sup>

These studies show that testing with MP detects very few cases of sensitization to fine fragrances (perfumes) and fragrances in rinse-off and leave-on cosmetic products that have not already been detected by a positive patch test reaction to FM I. A study from Spain, however, suggests that some fragrance allergies that are not detected by FM I can indeed be detected by MP.<sup>48</sup> In this investigation, 86 patients among 1253 routinely tested individuals, selected on the basis of one or more positive fragrance indicators or suspicion of fragrance contact allergy despite negative markers, were patch tested with a fragrance series. This series included the eight ingredients of FM I, the six ingredients of FM II, nine essential oils or botanical extracts (jasmine and lavender), and several ingredients of MP (eugenol, isoeugenol, cinnamyl alcohol, benzyl alcohol, vanillin, and farnesol). Twelve patients in the group of 86 tested with the fragrance series had single MP reactivity, and no reactivity to any other marker. Of these, three (25%) had positive reactions in the fragrance series. In the total population of 1253 patients routinely tested, 80 (6.4%) reacted to MP. Of these, 48 were single positives, not reacting to FM I or FM II. If 25% of these were to indicate fragrance allergy, 12 (ie, 0.96% of the total test population) patients with fragrance sensitization would have been missed by not patch testing with MP.<sup>48</sup> It

should be realized, of course, that this calculation is based on only three positive reactions to MP, so the evidence is rather weak.

## 6.2 | Added value of testing MP: ingredients

Another approach to assess the added value of MP as fragrance indicator is to look at its ingredients. Coniferyl benzoate, which has been considered to be the most important sensitizer in MP,<sup>2,11</sup> is not used in fragrances.<sup>145</sup> This means that any reaction to it is, by definition, not relevant as far as fragrance allergy is concerned, unless cross-reactivity is a possibility. The ingredients eugenol, isoeugenol and cinnamyl alcohol are present in FM I, and farnesol is present in FM II. In order to identify other possible allergens, studies performing routine testing with the other ingredients of MP that have previously shown positive reactions in patients reacting to MP (Table 2) were searched for; their results are shown in Table 3.

No data were found for cinnamyl cinnamate, coniferyl alcohol, benzaldehyde, methyl cinnamate, benzyl isoferulate, and isoferulic acid. The last three of these are very unlikely to be important allergens in MP, as they caused only 0% to 4% (methyl cinnamate), 2% (benzyl isoferulate) and 1% (isoferulic acid) positive reactions in a group of 102 MP-allergic patients.<sup>11</sup> Most of the other ingredients have had very low frequencies of sensitization, in the range of 0% to 0.4%, in routine testing (Table 3). Benzoic acid caused 4.9% and 5.7% positive reactions in two studies from the same clinic in the United States, but the test substance used (5% pet.) is known to cause irritant reactions,<sup>5</sup> and there were many ?+ reactions, which were counted as positive, in disagreement with international convention. In one investigation,

**TABLE 3** Frequency of contact allergy to ingredients of *Myroxylon pereirae* resin (MP) in routine testing

Compound	MP-positive <sup>b</sup>	Studies performing routine testing (reference numbers in parentheses) <sup>a</sup>									
		(47)	(118)	(146)	(46)	(45)	(147)	(148)	(35)	(5)	
Cinnamic acid	13%-32%										1.5% <sup>c</sup>
Cinnamyl cinnamate	20%-25%										
Benzoic acid	8%-20%										4.9%-5.7% <sup>d</sup>
Benzyl alcohol	8%-20%	0.1%	0.3%	0%	0.2%	0.1%	0.3%	0.1%	0.4%		0.2%-1.0%
Benzyl cinnamate	3%-19%	0.05%	0.3%	0.3%	0.2%	0.1%	0%	0.02%	0%		
Vanillin	0%-17%										0.3%
Coniferyl alcohol	14%										
Benzyl benzoate	0%-12%	0.1%	0.0%	0.3%	0.1%	0%	0%	0%	0%		
Benzaldehyde	10%										
Nerolidol	3%-6%										3.5% <sup>e</sup>
Methyl cinnamate	0%-4%										
Benzyl isoferulate	2%										
Isoferulic acid	1%										

<sup>a</sup>In the table, the percentages of positive reactions are shown; a blank means that the substance has not been tested in these (or any other) studies.

<sup>b</sup>Percentages reacting among patients allergic to MP (details in Table 2).

<sup>c</sup>Three positive reactions in 200 patients.

<sup>d</sup>Two studies from one US clinic; the test substance used (5% pet.) causes irritant reactions; there were many ?+ reactions, which were counted as positive (in disagreement with international convention); a large number of substances were tested, increasing the risk of false-positive reactions resulting from excited skin syndrome.

<sup>e</sup>Probably some irritant reactions; nerolidol was tested at 50% pet.

nerolidol caused 3.5% positive reactions (seven positives in 200 patients tested), but the test concentration was extremely high (50% pet.), and a number of the reactions are likely to have been irritant. Most interestingly, the quantitatively most important chemicals in MP, that is, benzyl cinnamate (up to 40%) and benzyl benzoate (up to 30%), have shown very low frequencies of sensitization, with a range of 0% to 0.3% for benzyl cinnamate (average, 0.12%; median, 0.08%) and a range of 0% to 0.3% for benzyl benzoate (average, 0.06%; median, 0.0%). This means that probably at least half of the MP used for patch testing is almost completely non-sensitizing.

A few other ingredients of MP are known allergens; these are shown in Table 4, with a summary of contact allergy reports. Three ( $\beta$ -caryophyllene,  $\beta$ -pinene, and  $\alpha$ -terpineol) have been patch tested in routine testing, and have yielded low rates of sensitization. Most others have been shown to be (minor or major) allergens in tea tree oil or turpentine oil. Limonene (as hydroperoxides) was recently shown to be a frequent contact allergen.<sup>47,50,151-155</sup> Of patients allergic to limonene hydroperoxides, 11% to 48% were also allergic to MP, which is a significant association. It is not very likely, however, that many of these reactions can be ascribed to limonene in MP: in all studies but

one, the percentages of positive reactions to FM I, which does not contain limonene, were higher. Also, limonene has been found in MP in one study only, by the use of solid-phase micro-extraction, which is a method for extracting trace organic compounds.<sup>7</sup>

## 7 | RESTRICTIVE DIETS IN PATIENTS ALLERGIC TO MP

As early as 1961, it was noted that the oral intake of MP or its individual components, such as cinnamic acid, vanillin, or eugenol, which are present as aromas in food and drink items, can cause a flare of dermatitis in some MP-allergic patients.<sup>2</sup> Later, in a number of patients sensitized to MP, dermatitis was found to resolve or improve after they had followed an MP-restrictive diet.<sup>105,106,108-110</sup> Oral administration of MP (provocation test) sometimes resulted in exacerbation of dermatitis.<sup>104,105,110</sup> Various studies on oral provocation with balsam of Peru and the effect of balsam of Peru-restrictive diets in patients allergic (and also in dermatitis patients not allergic) to MP have been performed, mostly between 1981 and 1996 by one group of Danish investigators.<sup>156-160</sup>

In the first study,<sup>156</sup> the investigators observed that the eczema of several patients with negative patch test results with MP could flare following ingestion of food items containing "balsams." In a preliminary open study, 42 individuals with eczema, in whom neither history nor standard patch tests had shown the cause of the dermatitis (nine with perianal dermatitis, 17 with bilateral hand eczema, and 16 with eczema at other sites), were challenged with 900 mg of MP orally once daily taken as capsules. Nine patients (21%) had unequivocal flares 1 to 3 days after the challenge with (sometimes generalized) pruritus and aggravation at the usual sites of the eczema. These nine patients with a positive challenge test result were instructed to avoid food items suspected to contain balsams for at least 1 month. At the end of this period, five (56%) patients showed clearance of all symptoms and signs of eczema.<sup>156</sup>

In a second study from these investigators,<sup>157</sup> during 1982 to 1984, placebo-controlled, double-blind oral challenges with MP 1 g once daily in 210 patients with various types of dermatitis were performed. Forty-five of them (21%) experienced a flare of their symptoms within 4 days after challenge with MP, but not after treatment with placebo. Of 17 patients with positive patch test reactions to MP, 10 (59%) had a positive challenge test result, including all four patients with vesicular hand dermatitis. Among MP-negative patients, the symptoms of 12 of 58 (21%) patients with vesicular hand eczema flared, as was the case in five of 18 (28%) individuals with anogenital dermatitis, and three of eight (38%) individuals with axillary eczema. Among individuals with other patterns of dermatitis, only six (9%) had a positive oral challenge test result. Patients with a positive reaction to MP but a negative result with placebo were instructed to avoid food items suspected to contain balsams. Dietary restriction was followed by marked improvement or clearance of the dermatitis in approximately half of the patients who adhered to the diet for at least

**TABLE 4** Other allergenic ingredients not previously tested in *Myroxylon pereirae* resin (MP)-allergic patients

Constituent	Contact allergy reports <sup>5</sup>
$\beta$ -Caryophyllene	Routine testing with caryophyllene oxide: 0.5%, 0.6%, and 1.1%; in one study, all three positive patients co-reacted to colophonium; two case reports: essential oils as causative products
<i>p</i> -Cymene	One positive reaction in 64 patients allergic to tea tree oil <sup>149</sup>
Eucalyptol (1,8-cineole)	Two case reports: causative products tea tree oil and topical pharmaceutical
Limonene	Limonene hydroperoxides are very important allergens; significant association between a history of rash resulting from skin contact with citrus fruits and a positive patch test reaction to MP <sup>120</sup> ; limonene is the major ingredient in citrus peel oils <sup>150</sup> ; MP co-reactivity in 11%, <sup>47</sup> 13.5%, <sup>151</sup> 18%, <sup>152</sup> 21%, <sup>153</sup> 24%, <sup>154</sup> 33%, <sup>155</sup> and 48% <sup>50</sup> (higher frequency than with fragrance mix I [32%] in patients reacting to limonene hydroperoxides)
$\alpha$ -Pinene	Major allergen in turpentine oil (>50% positive reactions); a few case reports regarding essential oils
$\beta$ -Pinene	Routine testing: 0.2%, 9% and 37% positive reactions in patients allergic to turpentine oil
$\alpha$ -Terpinene	Important allergen in tea tree oil, reacting in three of four sensitized individuals <sup>149</sup>
4-Terpineol (terpinen-4-ol)	Minor allergen in tea tree oil with 5% positive reactions <sup>149</sup> ; six patients reacted to "terpineol" in topical pharmaceutical preparations
$\alpha$ -Terpineol	Routine testing: 0.1% and 0.2% positive reactions; minor allergen in turpentine oil; six patients reacted to "terpineol" in topical pharmaceutical preparations

1 month; only one of these patients had a positive patch test reaction to MP.<sup>157</sup>

In a subsequent publication by this group of authors, the results of long-term dietary restrictions were reported.<sup>158</sup> Sixty-four patients participated in this study. Twenty-four were patients who had positive patch test reactions to MP, and, in 40 individuals, the dermatitis had previously flared after oral challenge with MP. All 64 patients were asked to avoid food items suspected to contain balsams for 1 to 2 months, and the dermatitis of 37 (58%) cleared or improved markedly. If an improvement had taken place, the patient was asked to continue to diet moderately; 6 months to 3 years later, 30 (47%) felt that there was a long-term effect, and 27 still followed the diet instructions to some degree. In the subgroup of the 24 patients with positive patch test reactions to MP, 15 (63%) reported benefit from the diet.<sup>158</sup>

In yet another study by the same group,<sup>159</sup> the long-term effect of dietary restrictions was investigated in 15 patients who reacted positively to MP and/or FM, 13 of whom had a positive oral challenge test result. Most had vesicular hand dermatitis. Nine of 15 (60%) reported long-term improvement resulting from dietary restrictions. However, in a group of 12 patients with a negative patch test result with MP, but a positive challenge test result, a higher percentage (67%, 6/9) reported long-term improvement.<sup>159</sup> In a final study from this group, in 1996,<sup>160</sup> it was investigated whether the results of oral challenge with MP can predict possible benefit from a low-balsam diet. Forty-six patients with positive patch test reactions to MP and/or FM I and chronic dermatitis with a morphology consistent with systemic dermatitis had experienced improvement after using a low-balsam diet for 1 to 2 months, and continued to use it. Twenty-eight of these (71%) stated in a questionnaire mailed after 1 to 3 years that they had experienced long-term benefits from the dietary treatment. In the group of 22 with a positive oral provocation test result, 16 (73%) reported benefit; three of 10 (30%) who had a negative challenge test result, and nine of 14 (64%) of the patients in whom no oral challenge test had been performed reported benefit. This indicated that the oral challenge procedure offers only limited assistance in selecting patients who are likely to benefit from dietary treatment.<sup>160</sup>

The food items most commonly mentioned in the Danish studies by patients as causes of flare of dermatitis were spices, cinnamon, curry, vanilla, liver paste, wine, bitters, pickled herring, citrus fruit and citrus drinks, cake, ice cream, vegetables, candy, chocolate, tomatoes, and ketchup.<sup>158-160</sup> It should be appreciated that, in all of these studies, the symptoms were interpreted largely by the patients themselves, and no objective signs were observed by the investigators.

In a 1984 study from Finland,<sup>161</sup> a group of 118 MP-allergic patients were patch tested with a series of (powdered) spices. There were positive reactions in 48 (41%) individuals: cloves (46%), Jamaica pepper (21%), cinnamon (15%), ginger (6%), curry (6%), cardamom (4%), white pepper (3%), vanilla (3%), and paprika (3%). In a control group of MP-negative patients, only a few reactions were seen. Seventy-one MP-allergic patients had oral provocation tests performed with spices and seven (10%) had reactions, notably a vesicular reaction of the hands, but also two urticarial reactions; in three, the

patch test with spices gave a negative result. The author suggested that spices are potential but rare causes of contact dermatitis, and that they may also cause skin symptoms, most frequently a pompholyx reaction, as a consequence of internal exposure in patients with contact allergy to MP.<sup>161</sup>

Ten years later, the same author performed double-blind placebo-controlled peroral challenges with MP and spices in patients with delayed-type allergy to MP.<sup>162</sup> Twenty-nine patients previously reacting to MP 25% *per. were* tested with MP and spices. The second patch test with MP gave positive reactions in 17 (59%) of the 29 retested patients. Positive reactions to one or more spices were seen in five individuals (17%), all reacting to cloves and Jamaica pepper, and two reacting to cinnamon. One of the patients with positive patch test reactions to the spices did not react to balsam of Peru in the second patch test. Twenty-two patients were challenged perorally with 1 g of balsam of Peru and a spice mixture with equal parts of cinnamon, Jamaica pepper, cloves, and vanilla sugar, in two capsules of 200 mg each, and glucose as placebo. Eight of the 22 patients (36%) reacted to the active substances, but not to placebo (of whom four were MP-positive and four were MP-negative). The eight patients with positive oral challenge test results showed an increase of at least 30% in the number of palmar vesicles caused by ingested balsam of Peru or spices. It was concluded that it seems possible that ingested MP and related spices cause systemic allergic reactions in patients with delayed contact allergy to MP.<sup>162</sup>

In a retrospective study from the United States<sup>163</sup> published in 2001, of 45 patients allergic to MP and/or FM I in whom balsam dietary avoidance was recommended, 21 (47%) reported complete or significant improvement primarily related to dietary modification. Nine of 45 did not follow the recommended diet, and, of these, only one (11%) had significant improvement. The food items most commonly mentioned as causes of flare-up of dermatitis were tomatoes (which contain coniferyl alcohol and cinnamyl alcohol,<sup>164,165</sup>), citrus, spices, cola or soda, chocolate, chili, cinnamon, beer or wine, and vinegar. This study relied entirely on patients' subjective opinions.<sup>163</sup>

## 8 | DISCUSSION

In this discussion, we will focus on the following questions: (a) how useful are restrictive diets in MP-allergic patients; and (b) what is the significance of positive patch test reactions to MP and what is the value of MP in the baseline series?

### 8.1 | How useful are restrictive diets in MP-allergic patients?

The answer to the question "What, if any, is the value of a low-balsam diet?"<sup>166</sup> in MP-allergic patients is, at this moment, not clear-cut. No prospective studies to support advice regarding dietary restrictions have been published in the last 25 years, and most of the work on this subject does not meet current scientific criteria. For example, almost all studies relied on the patients' own observations, exacerbations

were not verified by the investigators,<sup>166</sup> the placebo effect of following a diet is probably considerable, and provocation and elimination experiments after initial improvement on a diet have rarely been performed, or at least have not been published. In addition, there is a lack of validated evidence with regard to the content of MP, spices containing MP ingredients (eg, eugenol in cloves and cinnamon) or individual MP components in various foods, and, consequently, there is no objective scientific measure with which to quantify dietary balsam exposure. Oral provocation tests with MP may give positive results, but this may also occur in MP-negative patients, and the results of oral provocation tests do not reliably predict the benefit of dietary intervention. In one study, patients with a positive provocation test result but a negative patch test result with MP had the same chance of experiencing dietary benefits as MP-positive individuals.<sup>159</sup> Provocation tests with the spices cloves (containing eugenol) and cinnamon have given positive results in some MP-allergic individuals,<sup>161,162</sup> but these authors did not investigate the effect of dietary restrictions of these products.

From these studies, the following—tentative—conclusions may be drawn and suggestions made. Some patients with dermatitis, especially those with forms suggestive of systemic allergic dermatitis (vesicular hand dermatitis, other types of symmetrical dermatitis of the hands or feet, anogenital dermatitis, symmetrical dermatitis in the large skin folds, such as the axillae, and the groins<sup>167</sup>), may benefit from a diet that restricts foods containing balsams, and certain spices such as cinnamon, cloves, and vanilla. Especially, patients with positive patch test reactions to MP (and probably also some patients who not react to MP but react to FM I), but also patients with negative MP patch test results,<sup>156,157</sup> may benefit. An oral provocation test is not very helpful in predicting the results of a diet, although following a diet after a negative test result is less likely to be beneficial than following a diet after a positive provocation test result. As restrictive diets are difficult to adhere to and often disrupt normal social life, it is recommended that dietary treatment be limited to those individuals with severe, long-standing dermatitis who respond poorly to conventional treatment.<sup>158</sup> Initially, the patients can be placed on a restrictive diet for at least 4 weeks, and, if the dermatitis significantly improves, long-term compliance can be recommended. Subsequently, one food group can be reintroduced into the diet every several weeks to ascertain whether this particular substance exacerbates the dermatitis. Those foods worsening the eruption would then have to be avoided permanently.<sup>168</sup>

A recent, possibly useful, suggestion is to divide the food allergens in MP into the following groups: eugenol, cinnamate, vanillin, benzoate, ferulic acid, and coniferin.<sup>169</sup> By establishing to which of these the MP-allergic patient reacts, it will be possible to give more specific instructions which foods, drinks and spices are best avoided. The authors suggested the following screening allergens for this: eugenol and isoeugenol (eugenol group), vanillin (vanillin group), cinnamal, cinnamyl alcohol, and benzyl cinnamate (cinnamate group), benzoic acid and sodium benzoate (benzoate group), ferulic acid (ferulic acid group), and coniferyl alcohol (coniferin group). The authors of this article also provide a table with a large number of foods, drinks, and

spices, indicating which of the food allergen groups are present in them (and therefore need to be avoided by allergic patients).<sup>169</sup> Studies on the efficacy of such measures appear not to have been published thus far.

Detailed lists of high-risk processed foods (foods and drinks that frequently contain ingredients high in MP) and of primary ingredients (vanillin, eugenol, cinnamon, etc.) can be found at <https://www.dermatitisacademy.com/bop-diet/#toggle-id-6> (last accessed March 4, 2019). However, one might start with avoiding citrus peels, spices such as cinnamon, cloves, vanilla, and curry, and products containing them, ice cream, flavoured beverages and colas, and tomatoes.

## 8.2 | What is the significance of positive patch test reactions to MP and what is the value of MP in the baseline series?

Reactions to MP 25% pet. are frequent in most countries, and are generally found in 4% to 8% of patients routinely tested for suspected contact dermatitis. Many such studies have been performed, but only a few have provided data on the relevance of positive MP patch test reactions, and only in a single study after 2000 were culprit products mentioned: topical pharmaceuticals and cosmetics.<sup>49</sup> In case series and case reports, the most frequently mentioned products causing allergic contact dermatitis were also topical pharmaceuticals, cosmetics, and—to a far lesser degree—foods and drinks.

There can be no doubt that pharmaceuticals containing MP used to be frequent causes of MP allergy, especially preparations used for their alleged wound healing properties.<sup>2</sup> This may explain the high percentages of patients with leg ulcers and/or stasis dermatitis who reacted to MP,<sup>52-59</sup> especially in France, where wound dressings containing MP were still being used for leg ulcers 10 years ago.<sup>54</sup> In other countries, however, such preparations are rarely used any more (Belgium<sup>13</sup>) or are not used at all (Denmark<sup>12</sup>). The author's conclusion is that sensitization to MP in topical pharmaceuticals cannot explain the current high rates of positive patch test reactions to MP.

In three studies from Belgium,<sup>94,97,98</sup> MP was considered to be an important allergen in cosmetics, with 11.8% to 33.3% of the patients reacting to it. This may not, strictly speaking, be correct. Crude MP was banned by the IFRA in 1982, and is no longer used in perfumes (fine fragrances and perfumes in cosmetics and other products).<sup>15-17</sup> Extracts or distillates are allowed in low concentrations, but these products are little used.<sup>5</sup> Because of the well-known sensitization potential of MP, it is unlikely that cosmetic manufacturers would use crude MP. Indeed, in February 2019, MP was present in only six of 70 893 (0.008%) cosmetic products for which the composition is known in the EWG's Skin Deep Cosmetics Database.<sup>18</sup> There are no such data available in Europe. However, Belgian authors recently stated that pharmaceutical preparations containing MP are only rarely used in Belgium, and that few reactions to them have been observed after 2000.<sup>13</sup> Thus, the use of MP in cosmetics to some extent would be highly unlikely. Therefore, it was assumed that, in these Belgian studies, MP was considered to be a marker for fragrance allergy rather than a cosmetic ingredient, and that, in cases of allergy to fragrances



or fragranced cosmetics, the reaction to MP was scored as relevant; this has been confirmed by the main author (An Goossens, personal communication, January 2019).

In two Spanish studies, lower percentages (2% and 2.7%) of reactions to MP were stated to be the cause of cosmetic allergy.<sup>95,96</sup> However, products considered to be causative included a perfume and a deodorant,<sup>96</sup> which is highly likely to be incorrect, considering the long-standing IFRA ban on crude MP in fragrances and the impossibility of identifying MP derivatives in these products. The author's conclusion is that sensitization to MP in cosmetics cannot explain the current high rates of positive patch test reactions to MP.

The relationship between MP and foods and drinks has been discussed above. The oral route is not a very effective one for sensitization to occur, so most cases of dermatitis or exacerbations of dermatitis resulting from the ingestion of foods and drinks containing (or supposed to contain) MP or individual ingredients most result from, rather than being the cause of, sensitization to MP.

So, if topical pharmaceuticals, cosmetics and food and drinks are not responsible for MP sensitization, and other possible sources of contact with MP are not known, why then are there so many reactions to MP? The answer that is most likely to be correct is that people have previously become sensitized to one or more of its individual ingredients (most of which are fragrance chemicals), for example, by contact with perfumes, perfumed cosmetics, or non-cosmetic fragranced products, and this allergy subsequently becomes apparent by a positive patch test reaction to MP, which thus acts as an indicator of fragrance allergy. The notion that MP is a fragrance marker, a "natural fragrance mix," has existed since the 1960s,<sup>2-4</sup> and this is still the case, as, generally, 25% to 50% of patients with fragrance allergy proven by positive reactions to individual fragrance chemicals, essential oils, perfumes from cosmetic products or fine fragrances also react to MP.<sup>48,121,140,143,144</sup> However, FM I is a more sensitive marker than MP, and the key issue is how often MP shows relevant positive reactions, indicating fragrance sensitization, when FM I fails to do so. In other words: what is the added value of testing MP as well as FM I?

Although a high degree of co-reactivity between MP and FM I and vice versa is apparent, possibly because of common ingredients and well-known sensitizers such as eugenol, isoeugenol, and cinnamyl alcohol, generally, 50% to 75% of patients reacting to MP do not co-react to FM I (see the section "Cross-reactions, pseudo-cross-reactions, and co-reactions" above). Unfortunately, how many of these "single" reactions to MP are relevant has not been described in any investigation. However, in some well-designed studies from Denmark, testing with MP detected very few cases of sensitization to fine fragrances (perfumes) and fragrances in rinse-off and leave-on cosmetic products that had not already been detected by a positive patch test reaction to FM I.<sup>121,140,141</sup> From the data in a Spanish study,<sup>48</sup> the author calculated that nearly 1% of all routinely tested individuals may have had relevant MP reactions with negative results with FM I; however, the evidence for this is rather weak (see section "Added value of testing MP: number of cases identified" above). Thus, the data are currently insufficient to establish the added value of testing with MP.

Another approach to the subject of the usefulness of MP is to look at its ingredients. The exact spectrum of allergens in the MP materials used for patch testing that cause positive test reactions is currently unknown, but certainly includes isoeugenol, eugenol, and cinnamyl alcohol.<sup>20,47,118</sup> These cannot explain single positive reactions to MP, as they are also present, and in higher concentrations, in FM I. Coniferyl benzoate has been considered to be the most important sensitizer in MP.<sup>2,11</sup> However, assuming that patients with positive MP reactions have not had previous contact with the material itself, and because coniferyl benzoate is not used in fragrances<sup>145</sup> or other products except as an antifeedant (a substance that stops or inhibits feeding by a pest, and especially an insect),<sup>170</sup> it should not be a cause of positive reactions. Ingredients of MP that are possibly allergenic as shown by ingredient patch testing are shown in Table 2. None of these, or other ingredients of MP, appear to be important sensitizers (see section "Added value of testing MP: ingredients" above). In fact, the quantitatively most important chemicals in MP, that is, benzyl cinnamate (up to 40%) and benzyl benzoate (up to 30%), have shown very low frequencies of sensitization, with a range of 0% to 0.3%. This means that probably at least half of the MP used for patch testing is almost completely non-sensitizing. The author concludes that the ingredients of MP that cause single positive reactions to MP (and which therefore have added value if relevant) are unknown.

## 9 | CONCLUSIONS

MP 25% pet. in the baseline series causes many (4%-8%) positive patch test reactions in patients routinely tested for suspected contact dermatitis. Specific data on clinical relevance are largely lacking. Sensitization to MP in topical pharmaceuticals, cosmetics, foods and drinks or other known exposures cannot explain these high rates of sensitization. Most MP-positive patients have probably been sensitized previously by one or more of its ingredients, including isoeugenol, eugenol, and cinnamyl alcohol, because of their presence in fragrances or fragranced cosmetics or other scented products, and these sensitizations are subsequently shown by a positive reaction to MP, which thereby acts as an indicator of fragrance allergy, a "natural fragrance mix."

It is unknown to what degree MP identifies fragrance sensitizations that are not "picked up" by FM I, but there are indications that the added value of testing it as well as FM I is limited. Nevertheless, some 50% to 75% of patients with allergy to the MP test material do not react to FM I. How many of these reactions are relevant and what the sensitizers are is largely unknown. Benzyl cinnamate and benzyl benzoate, together making up approximately half of the substances, are probably hardly ever the culprit ingredients.

Regarding further research, the following studies may be helpful in determining the value of testing with MP in the baseline series and possibly improving patient care:

- Study 1 determines the percentage of single positive reactions to MP (ie, with negative results for FM I) and how many of these are

relevant, either by indicating fragrance allergy or from contact with products actually containing MP. These data can give an indication of the added value of MP and whether MP qualifies for—continued—inclusion in the European baseline series<sup>171</sup>.

- Study 2 investigates the composition of the commercial MP substances used for patch testing, and preferably also of other samples, both qualitatively and quantitatively; the MP supplier Chemotechnique Diagnostics has provided no information on the composition of its MP material; for the material provided to SmartPracticeCanada/Europe, it was revealed by the supplier only that it complies with the European Pharmacopoeia<sup>24</sup> and contains 48.1% (unspecified) balsamic esters (personal communications, February 2019).
- Study 3 tests groups of patients allergic to commercial MP test materials, preferably as shown by a positive patch test reaction on two occasions and with a negative patch test result with the emulsifier ingredient sorbitan sesquioleate (in Chemotechnique Diagnostics material) with a battery of its ingredients, as shown from study 2, to identify the most important causes of positive MP patch test reactions.
- Study 4 tests the chemicals most frequently reacting in study 3 in routine testing as an addition to MP, to determine the value of separate testing; if one to three chemicals appear to be the dominant haptens in study 3, they can be tested separately; if there are more allergenic ingredients, the formulation and testing of a “fragrance mix III” could be considered.

## CONFLICTS OF INTEREST

Anton de Groot is the author of the book *Monographs in Contact Allergy, Volume II—Fragrances and Essential Oils*, Boca Raton, FL, USA: CRC Press Taylor & Francis Group, 2019, which is referred to repeatedly in this article and of which this is a shortened but strongly adapted version.

## ORCID

Anton C. de Groot  <https://orcid.org/0000-0002-6666-7292>

## REFERENCES

1. Bonnevie P. Harze-Balsame, namentlich Kolophonium, Dammer (Heftplaster), Perubalsam, Shellack, Kautschuk. *Aethiologie und Pathogenese der Ekzemplkrankheiten*. Copenhagen, Denmark: Nyt Nordisk Forlag; 1939:153-185.
2. Hjorth N. Eczematous allergy to balsams. *Acta Derm Venereol*. 1961; 41(suppl 46):1-216.
3. Hjorth N. The Prosser-White oration 1980. Skin reactions to balsams and perfumes. *Clin Exp Dermatol*. 1982;7:1-9.
4. Rothenborg HW, Hjorth N. Allergy to perfumes from toilet soaps and detergents in patients with dermatitis. *Arch Dermatol*. 1968;97: 417-421.
5. de Groot AC. *Monographs in Contact Allergy, Volume II—Fragrances and Essential Oils*. Boca Raton, FL: CRC Press Taylor & Francis Group; 2019.
6. Hausen BM, Simatupang T, Bruhn G, Evers P, Koenig WA. Identification of new allergenic constituents and proof of evidence for coniferyl benzoate in Balsam of Peru. *Am J Contact Dermat*. 1995;6: 199-208.
7. Mammerler V. Contribution to the Analysis and Quality Control of Peru Balsam [PhD Thesis]. Vienna, Austria: University of Vienna; 2007. [http://othes.univie.ac.at/4056/1/2009-03-23\\_0201578.pdf](http://othes.univie.ac.at/4056/1/2009-03-23_0201578.pdf). Accessed February 18, 2019.
8. US National Plant Germplasm System. Taxon: *Myroxylon balsamum* (L.) Harms var. *pereirae* (Royle) Harms. <https://npgsweb.ars-grin.gov/gringlobal/taxonomydetail.aspx?70454>. Accessed February 18, 2019.
9. Amado A, Taylor JS. Balsam of Peru or Balsam of El Salvador? *Contact Dermatitis*. 2006;55:119.
10. European Medicines Agency. Committee on Herbal Medicinal Products (HMPC). Assessment report on *Myroxylon balsamum* (L.) Harms var. *pereirae* (Royle) Harms, balsamum; May 31, 2016, EMA/HMPC/712648/2014. [https://www.ema.europa.eu/documents/herbal-report/final-assessment-report-myroxylon-balsamum-l-harms-var-pereirae-royle-harms-balsamum\\_en.pdf](https://www.ema.europa.eu/documents/herbal-report/final-assessment-report-myroxylon-balsamum-l-harms-var-pereirae-royle-harms-balsamum_en.pdf). Accessed February 18, 2019.
11. Hausen BM. Contact allergy to Balsam of Peru. II. Patch test results in 102 patients with selected balsam of Peru constituents. *Am J Contact Dermat*. 2001;12:93-102.
12. Thyssen JP, Carlsen BC, Menné T, Johansen JD. Trends of contact allergy to fragrance mix I and *Myroxylon pereirae* among Danish eczema patients tested between 1985 and 2007. *Contact Dermatitis*. 2008;59:238-244.
13. Gilissen L, Huygens S, Goossens A. Allergic contact dermatitis caused by topical herbal remedies: importance of patch testing with the patients' own products. *Contact Dermatitis*. 2018;78:177-184.
14. Johansen JD. Contact allergy to fragrances: clinical and experimental investigations of the fragrance mix and its ingredients. *Contact Dermatitis*. 2002;46(suppl 3):1-31.
15. International Fragrance Association (IFRA). Standard Peru balsam crude; 2007. <http://www.ifraorg.org/en-us/standards-library#.XGqVGuhKiUk>. Accessed February 18, 2019.
16. Nardelli A, Carbonez A, Ottoy W, Drieghe J, Goossens A. Frequency of and trends in fragrance allergy over a 15-year period. *Contact Dermatitis*. 2008;58:134-141.
17. Api AM. Only Peru balsam extracts or distillates are used in perfumery. *Contact Dermatitis*. 2006;54:179.
18. EWG's Skin Deep Cosmetics Database. <https://www.ewg.org/skindeep/search.php?query=myroxylon+pereirae>. Accessed February 18, 2019.
19. International Fragrance Association (IFRA). Standard Peru balsam extracts and distillates; 2008. <http://www.ifraorg.org/en-us/standards-library>. Accessed February 18, 2019.
20. Nardelli A, Carbonez A, Drieghe J, Goossens A. Results of patch testing with fragrance mix 1, fragrance mix 2, and their ingredients, and *Myroxylon pereirae* and colophonium, over a 21-year period. *Contact Dermatitis*. 2013;68:307-313.
21. Seo SM, Park HM, Park IK. Larvicidal activity of ajowan (*Trachyspermum ammi*) and Peru balsam (*Myroxylon pereira*) oils and blends of their constituents against mosquito, *Aedes aegypti*, acute toxicity on water flea, *Daphnia magna*, and aqueous residue. *J Agric Food Chem*. 2012;60:5909-5914.
22. Leung AY, Foster S. *Encyclopedia of Common Natural Ingredients Used in Food, Drugs, and Cosmetics*. 2nd ed. New York: John Wiley & Sons, Inc; 1996.
23. Plant Therapy. [https://www.planttherapy.com/test\\_reports/Peru%20Balsam%20PN0100.pdf](https://www.planttherapy.com/test_reports/Peru%20Balsam%20PN0100.pdf). Accessed February 18, 2019.
24. Council of Europe. *European Pharmacopoeia, 8th ed. Peru balsam—Balsamum peruvianum*. Nördlingen, Germany: CH Beck; 2013. (01/2008:0754).

25. Ananda Apothecary, Boulder, Colorado, USA. Balsam (Peru) essential oil. <https://www.anandaapothecary.com/peru-balsam-essential-oil>. Accessed February 18, 2019.
26. Uter W, Fießler C, Gefeller O, Geier J, Schnuch A. Contact sensitization to fragrance mix I and II, to *Myroxylon pereirae* resin and oil of tupentine: multifactorial analysis of risk factors based on data of the IVDK network. *Flav Fragr J*. 2015;30:255-263.
27. Lindberg M, Edman B, Fischer T, Stenberg B. Time trends in Swedish patch test data from 1992 to 2000. A multi-centre study based on age- and sex-adjusted results of the Swedish standard series. *Contact Dermatitis*. 2007;56:205-210.
28. Machovcova A, Dastychova E, Kostalova D, et al. Common contact sensitizers in the Czech Republic. Patch test results in 12,058 patients with suspected contact dermatitis. *Contact Dermatitis*. 2005;53:162-166.
29. Akyol A, Boyvat A, Peksari Y, Gurgey E. Contact sensitivity to standard series allergens in 1038 patients with contact dermatitis in Turkey. *Contact Dermatitis*. 2005;52:333-337.
30. Fall S, Bruze M, Isaksson M, et al. Contact allergy trends in Sweden—a retrospective comparison of patch test data from 1992, 2000, and 2009. *Contact Dermatitis*. 2015;72:297-304.
31. Silvestre JF, Mercader P, González-Pérez R, et al. Sensitization to fragrances in Spain: a 5-year multicentre study (2011-2015). *Contact Dermatitis*. 2019;80:94-100.
32. Alinaghi F, Bennike NH, Egeberg A, Thyssen JP, Johansen JD. Prevalence of contact allergy in the general population: a systematic review and meta-analysis. *Contact Dermatitis*. 2019;80:77-85.
33. Thyssen JP, Uter W, Schnuch A, Linneberg A, Johansen JD. 10-year prevalence of contact allergy in the general population in Denmark estimated through the CE-DUR method. *Contact Dermatitis*. 2007;57:265-272.
34. Schnuch A, Uter W, Geier J, Gefeller O. Epidemiology of contact allergy: an estimation of morbidity employing the clinical epidemiology and drug-utilization research (CE-DUR) approach. *Contact Dermatitis*. 2002;47:32-39.
35. Dittmar D, Schuttelaar MLA. Contact sensitization to hydroperoxides of limonene and linalool: results of consecutive patch testing and clinical relevance. *Contact Dermatitis*. 2019;80:101-109.
36. Frosch PJ, Johansen JD, Schuttelaar M-LA, et al. Patch test results with fragrance markers of the baseline series—analysis of the European Surveillance System on Contact Allergies (ESSCA) network 2009–2012. *Contact Dermatitis*. 2015;73:163-171.
37. DeKoven JG, Warshaw EM, Zug KA, et al. North American Contact Dermatitis Group patch test results: 2015-2016. *Dermatitis*. 2018;29:297-309.
38. Uter W, Aberer W, Armario-Hita JC, et al. Current patch test results with the European baseline series and extensions to it from the "European Surveillance System on Contact Allergy" network, 2007-2008. *Contact Dermatitis*. 2012;67:9-19.
39. ESSCA Writing Group. The European Surveillance System of Contact Allergies (ESSCA): results of patch testing the standard series, 2004. *J Eur Acad Dermatol Venereol*. 2008;22:174-181.
40. Uter W, Hegewald J, Aberer W, et al. The European standard series in 9 European countries, 2002/2003—first results of the European Surveillance System on Contact Allergies. *Contact Dermatitis*. 2005;53:136-145.
41. Bruynzeel DP, Diepgen TL, Andersen KE, et al. Monitoring the European Standard Series in 10 centres 1996–2000. *Contact Dermatitis*. 2005;53:146-152.
42. Uter W, Rämisch C, Aberer W, et al. The European baseline series in 10 European countries, 2005/2006—results of the European Surveillance System on Contact Allergies (ESSCA). *Contact Dermatitis*. 2009;61:31-38.
43. Uter W, Amario-Hita JC, Balato A, et al. European Surveillance System on Contact Allergies (ESSCA): results with the European baseline series, 2013/14. *J Eur Acad Dermatol Venereol*. 2017;31:1516-1525.
44. Warshaw EM, Zug KA, Belsito DV, et al. Positive patch-test reactions to essential oils in consecutive patients: results from North America and Central Europe. *Dermatitis*. 2017;28:246-252.
45. Heisterberg MV, Menné T, Johansen JD. Contact allergy to the 26 specific fragrance ingredients to be declared on cosmetic products in accordance with the EU cosmetic directive. *Contact Dermatitis*. 2011;65:266-275.
46. Mann J, McFadden JP, White JML, White IR, Banerjee P. Baseline series fragrance markers fail to predict contact allergy. *Contact Dermatitis*. 2014;70:276-281.
47. Ung CY, White JML, White IR, Banerjee P, McFadden JP. Patch testing with the European baseline series fragrance markers: a 2016 update. *Br J Dermatol*. 2018;178:776-780.
48. Cuesta L, Silvestre JF, Toledo F, Lucas A, Perez-Crespo M, Ballester I. Fragrance contact allergy: a 4-year retrospective study. *Contact Dermatitis*. 2010;63:77-84.
49. Avalos-Peralta P, García-Bravo B, Camacho FM. Sensitivity to *Myroxylon pereirae* resin (balsam of Peru). A study of 50 cases. *Contact Dermatitis*. 2005;52:304-306.
50. Bråred Christensson J, Hellsén S, Börje A, Karlberg A-T. Limonene hydroperoxide analogues show specific patch test reactions. *Contact Dermatitis*. 2014;70:291-299.
51. Toholka R, Wang Y-S, Tate B, et al. The first Australian Baseline Series: recommendations for patch testing in suspected contact dermatitis. *Australas J Dermatol*. 2015;56:107-115.
52. Saap L, Fahim S, Arsenault E, et al. Contact sensitivity in patients with leg ulcerations: a North American study. *Arch Dermatol*. 2004;140:1241-1246.
53. Erfurt-Berge C, Geier J, Mahler V. The current spectrum of contact sensitization in patients with chronic leg ulcers or stasis dermatitis—new data from the Information Network of Departments of Dermatology (IVDK). *Contact Dermatitis*. 2017;77:151-158.
54. Barbaud A, Collet E, Le Coz CJ, Meaume S, Gillois P. Contact allergy in chronic leg ulcers: results of a multicentre study carried out in 423 patients and proposal for an updated series of patch tests. *Contact Dermatitis*. 2009;60:279-287.
55. Jankićević J, Vesić S, Vukićević J, Gajić M, Adamić M, Pavlović MD. Contact sensitivity in patients with venous leg ulcers in Serbia: comparison with contact dermatitis patients and relationship to ulcer duration. *Contact Dermatitis*. 2008;58:32-36.
56. Zmudzinska M, Czarnecka-Operacz M, Silny W, Kramer L. Contact allergy in patients with chronic venous leg ulcers—possible role of chronic venous insufficiency. *Contact Dermatitis*. 2006;54:100-105.
57. Machel L, Couhe C, Perrinaud A, Hoarau C, Lorette G, Vaillant L. A high prevalence of sensitization still persists in leg ulcer patients: a retrospective series of 106 patients tested between 2001 and 2002 and a meta-analysis of 1975-2003. *Br J Dermatol*. 2004;150:929-935.
58. Geier J, Erfurt-Berge C, Mahler V. Hautpflege bei chronisch venöser Insuffizienz. Was ist aus allergologischer Sicht zu berücksichtigen? *Phlebologie*. 2018;47:199-204.
59. Artüz F, Yılmaz E, Külcü Çakmak S, Polat Düzgün A. Contact sensitization in patients with chronic leg ulcers. *Int Wound J*. 2016;13:1190-1192.
60. Larsen WG. Perfume dermatitis. A study of 20 patients. *Arch Dermatol*. 1977;113:623-626.
61. Uter W, Geier J, Schnuch A, Frosch PJ. Patch test results with patients' own perfumes, deodorants and shaving lotions: results of the IVDK 1998-2002. *J Eur Acad Dermatol Venereol*. 2007;21:374-379.
62. O'Gorman SM, Torgerson RR. Contact allergy in cheilitis. *Int J Dermatol*. 2016;55:e386-e391.

63. Zug KA, Kornik R, Belsito DV, et al. Patch-testing North American lip dermatitis patients: data from the North American Contact Dermatitis Group, 2001 to 2004. *Dermatitis*. 2008;19:202-208.
64. Uter W, Balzer C, Geier J, Frosch PJ, Schnuch A. Patch testing with patients' own cosmetics and toiletries—results of the IVDK, 1998–2002. *Contact Dermatitis*. 2005;53:226-233.
65. Strauss RM, Orton DI. Allergic contact cheilitis in the United Kingdom: a retrospective study. *Am J Contact Dermat*. 2003;14:75-77.
66. Wetter DA, Yiannias JA, Prakash AV, Davis MDP, Farmer SA, el-Azhary RA. Results of patch testing to personal care product allergens in a standard series and a supplemental cosmetic series: an analysis of 945 patients from the Mayo Clinic Contact Dermatitis Group, 2000-2007. *J Am Acad Dermatol*. 2010;63:789-798.
67. Wöhlrl S, Hemmer W, Focke M, Götz M, Jarisch R. The significance of fragrance mix, balsam of Peru, colophony and propolis as screening tools in the detection of fragrance allergy. *Br J Dermatol*. 2001;145:268-273.
68. An S, Lee AY, Lee CH, et al. Fragrance contact dermatitis in Korea: a joint study. *Contact Dermatitis*. 2005;53:320-323.
69. Warshaw EM, Buchholz HJ, Belsito DV, et al. Allergic patch test reactions associated with cosmetics: retrospective analysis of cross-sectional data from the North American Contact Dermatitis Group, 2001-2004. *J Am Acad Dermatol*. 2009;60:23-38.
70. Dinkloh A, Worm M, Geier J, Schnuch A, Wollenberg A. Contact sensitization in patients with suspected cosmetic intolerance: results of the IVDK 2006-2011. *J Eur Acad Dermatol Venereol*. 2015;29:1071-1081.
71. Hillen U, Grabbe S, Uter W. Patch test results in patients with scalp dermatitis: analysis of data of the Information Network of Departments of Dermatology. *Contact Dermatitis*. 2007;56:87-93.
72. Wenk KS, Ehrlich AE. Fragrance series testing in eyelid dermatitis. *Dermatitis*. 2012;23:22-26.
73. Landeck L, John SM, Geier J. Periorbital dermatitis in 4779 patients—patch test results during a 10-year period. *Contact Dermatitis*. 2014;70:205-212.
74. Cooper SM, Shaw S. Eyelid dermatitis: an evaluation of 232 patch test patients over 5 years. *Contact Dermatitis*. 2000;42:291-293.
75. Herbst RA, Uter W, Pirker C, Geier J, Frosch PJ. Allergic and non-allergic periorbital dermatitis: patch test results of the Information Network of the Departments of Dermatology during a 5-year period. *Contact Dermatitis*. 2004;51:13-19.
76. Feser A, Plaza T, Vogelsgang L, Mahler V. Periorbital dermatitis—a recalcitrant disease: causes and differential diagnoses. *Br J Dermatol*. 2008;159:858-863.
77. Assier H, Tetart F, Avenel-Audran M, et al. Is a specific eyelid patch test series useful? Results of a French prospective study. *Contact Dermatitis*. 2018;79:157-161.
78. Landeck L, Schalock PC, Baden LA, Gonzalez E. Periorbital contact sensitization. *Am J Ophthalmol*. 2010;150:366-370.
79. Schwensen JF, Johansen JD, Veien NK, et al. Occupational contact dermatitis in hairdressers: an analysis of patch test data from the Danish Contact Dermatitis Group, 2002–2011. *Contact Dermatitis*. 2014;70:233-237.
80. Uter W, Lessmann H, Geier J, Schnuch A. Contact allergy to ingredients of hair cosmetics in female hairdressers and clients: an 8-year analysis of IVDK data. *Contact Dermatitis*. 2003;49:236-240.
81. Uter W, Lessmann H, Geier J, Schnuch A. Contact allergy to hair-dressing allergens in female hairdressers and clients—current data from the IVDK 2003–2006. *J Dtsch Dermatol Ges*. 2007;5:993-1001.
82. Uter W, Gefeller O, John SM, Schnuch A, Geier J. Contact allergy to ingredients of hair cosmetics—a comparison of female hairdressers and clients based on IVDK 2007–2012 data. *Contact Dermatitis*. 2014;71:13-20.
83. Carøe TK, Ebbehøj NE, Agner T. Occupational dermatitis in hairdressers—influence of individual and environmental factors. *Contact Dermatitis*. 2017;76:146-150.
84. Molin S, Bauer A, Schnuch A, Geier J. Occupational contact allergy in nurses: results from the Information Network of Departments of Dermatology 2003–2012. *Contact Dermatitis*. 2015;72:164-171.
85. Higgins CL, Palmer AM, Cahill JL, Nixon RL. Occupational skin disease among Australian healthcare workers: a retrospective analysis from an occupational dermatology clinic, 1993–2014. *Contact Dermatitis*. 2016;75:213-222.
86. Ibler KS, Jemec GBE, Garvey LH, Agner T. Prevalence of delayed-type and immediate-type hypersensitivity in healthcare workers with hand eczema. *Contact Dermatitis*. 2016;75:223-229.
87. Foussereau J. Allergy to Dermophil Indien. *Contact Dermatitis*. 1975;1:257.
88. Melisana Healthcare. Dermophil. <https://www.melisana.ch/en/brands/dermophil.html>. Accessed February 18, 2019.
89. Nardelli A, D'Hooge E, Drieghe J, Doods M, Goossens A. Allergic contact dermatitis from fragrance components in specific topical pharmaceutical products in Belgium. *Contact Dermatitis*. 2009;60:303-313.
90. Tan S, Tam MM, Nixon RL. Allergic contact dermatitis to *Myroxylon pereirae* (Balsam of Peru) in papaw ointment causing cheilitis. *Australas J Dermatol*. 2011;52:222-223.
91. Hill H, Jacob SE. Peri-anal ulcerations in a patient with essential pruritus. *Dermatitis*. 2015;26:292-293.
92. Bruynzeel D, van den Hoogenband H, Koedijk F. Purpuric vasculitis-like eruption in a patient sensitive to balsam of Peru. *Contact Dermatitis*. 1984;11:207-209.
93. Meneghini CL, Angelini G. Secondary polymorphic eruptions in allergic contact dermatitis. *Dermatologica*. 1981;163:63-70. (data cited in ref. 92).
94. Goossens A. Cosmetic contact allergens. *Cosmetics*. 2016;3:5. <https://doi.org/10.3390/cosmetics3010005>.
95. Zaragoza-Ninet V, Blasco Encinas R, Vilata-Corell JJ, et al. Allergic contact dermatitis due to cosmetics: a clinical and epidemiological study in a tertiary hospital. *Actas Dermosifiliogr*. 2016;107:329-336.
96. Laguna C, de la Cuadra J, Martín-González B, Zaragoza V, Martínez-Casimiro L, Alegre V. Allergic contact dermatitis to cosmetics. *Actas Dermosifiliogr*. 2009;100:53-60.
97. Doods-Goossens A, Kerre S, Drieghe J, Bossuyt L, DeGreef H. Cosmetic products and their allergens. *Eur J Dermatol*. 1992;2:465-468.
98. Broeckx W, Blondeel A, Doods-Goossens A, Achten G. Cosmetic intolerance. *Contact Dermatitis*. 1987;16:189-194.
99. Fisher AA. Perfume dermatitis in children sensitized to balsam of Peru in topical agents. *Cutis*. 1990;45:21-23.
100. Adams RM, Maibach HI, for the North American Contact Dermatitis Group. A five-year study of cosmetic reactions. *J Am Acad Dermatol*. 1985;13:1062-1069.
101. Fisher AA. The clinical significance of patch test reactions to balsam of Peru. *Cutis*. 1976;13:910-913.
102. Rietschel RL, Fowler JF Jr, eds. *Fisher's Contact Dermatitis*. 6th ed. Hamilton, Ontario, Canada: Decker Inc.; 2008.
103. Pirilä V. Endogenous contact eczema. *Allerg Asthma*. 1970;16:15-19.
104. Bedello PG, Goitre M, Cane D. Contact dermatitis and flare from food flavouring agents. *Contact Dermatitis*. 1982;8:143-144.
105. Pfützner W, Thomas P, Niedermeier A, Pfeiffer C, Sander C, Przybilla B. Systemic contact dermatitis elicited by oral intake of balsam of Peru. *Acta Derm Venereol*. 2003;83:294-295.
106. Jacob SE, Steele T. Tongue erosions and diet cola. *Ear Nose Throat J*. 2007;86:232-233.
107. Herro EM, Jacob SE. Systemic contact dermatitis—kids and ketchup. *Pediatr Dermatol*. 2013;30:e32-e33.



108. Matiz C, Jacob SE. Systemic contact dermatitis in children: how an avoidance diet can make a difference. *Pediatr Dermatol.* 2011;28:368-374.
109. Nanda A, Wasan A. Allergic contact dermatitis to balsam of Peru. *Ann Allergy Asthma Immunol.* 2016;117:208-209.
110. Niedermeier A, Pfütznner W, Thomas P, Przybilla B. Hämatogen-allergisches Kontaktexzema auf Perubalsam (Systemic contact eczema against Balsam of Peru). *J Dtsch Dermatol Ges.* 2003;1:719-721.
111. Panconesi E, Sertoli A, Spallazani P, Giorgini S. Balsam of Peru sensitivity from a perfumed cutting fluid in a laser factory. *Contact Dermatit.* 1980;6:297.
112. Øxholm A, Heidenheim M, Larsen E, Batsberg W, Menné T. Extraction and patch testing of methylcinnamate, a newly recognized fraction of balsam of Peru. *Am J Contact Dermat.* 1990;1:43-46.
113. Mitchell JC, Calnan CD, Clendenning WE, et al. Patch testing with some components of balsam of Peru. *Contact Dermatit.* 1976;2:57-58.
114. Rudzki E, Grzywa Z. Dermatitis from propolis. *Contact Dermatit.* 1983;9:40-45.
115. Jordan WP. Clothing and shoe dermatitis. *Postgrad Med.* 1972;52:143-148.
116. Goossens A, Blondeel S, Zimerson E. Resorcinol monobenzoate: a potential sensitizer in a computer mouse. *Contact Dermatit.* 2002;47:235.
117. Ljunggren B. Contact dermatitis to estradiol benzoate. *Contact Dermatit.* 1981;7:141-144.
118. Schnuch A, Uter W, Geier J, Lessmann H, Frosch PJ. Sensitization to 26 fragrances to be labelled according to current European regulation. Results of the IVDK and review of the literature. *Contact Dermatit.* 2007;57:1-10.
119. Carlsen BC, Menné T, Johansen JD. Associations between baseline allergens and polysensitization. *Contact Dermatit.* 2008;59:96-102.
120. Johansen JD, Anderson TF, Veien N, Avnstorp C, Andersen KE, Menné T. Patch testing with markers of fragrance contact allergy. Do clinical tests correspond to patients' self-reported problems? *Acta Derm Venereol.* 1997;77:149-153.
121. Johansen JD, Rastogi SC, Menné T. Contact allergy to popular perfumes: assessed by patch test, use test and chemical analysis. *Br J Dermatol.* 1996;135:419-422.
122. Rudzki E, Rebandel P. 100 patients positive to balsam of Peru observed in Warsaw (Poland). *Contact Dermatit.* 2006;55:255.
123. Belsito DV, Fowler JF Jr, Sasseville D, Marks JG Jr, De Leo VA, Storrs FJ. Delayed-type hypersensitivity to fragrance materials in a select North American population. *Dermatitis.* 2006;17:23-28.
124. Brasch J, Uter W, Geier J, Schnuch A. Associated positive patch test reactions to standard contact allergens. *Am J Contact Dermat.* 2001;12:197-202.
125. Bruze M. Simultaneous reactions to phenol-formaldehyde resins colophony/hydroabietyl alcohol and balsam of Peru/perfume mixture. *Contact Dermatit.* 1986;14:119-120.
126. Albert MR, Chang Y, González E. Concomitant positive reactions to allergens in a patch testing standard series from 1988-1997. *Am J Contact Dermat.* 1999;10:219-223.
127. Temesvári E, Németh I, Baló-Banga MJ, et al. Multicentre study of fragrance allergy in Hungary: immediate and late type reactions. *Contact Dermatit.* 2002;46:325-330.
128. Devos SA, Constandt L, Tupker RA, et al. Relevance of positive patch-test reactions to fragrance mix. *Dermatitis.* 2008;19:43-47.
129. Schnuch A, Lessmann H, Geier J, Frosch PJ, Uter W. Contact allergy to fragrances: frequencies of sensitization from 1996 to 2002. Results of the IVDK. *Contact Dermatit.* 2004;50:65-76.
130. Rudzki E, Grzywa Z. Allergy to perfume mixture. *Contact Dermatit.* 1986;15:115-116.
131. de Groot AC, Popova MP, Bankova VS. *An Update on the Constituents of Poplar-Type Propolis.* Wapserveen, The Netherlands: acdegroot publishing; 2014.
132. Hausen BM, Evers P, Stüwe H-T, König WA, Wollenweber E. Propolis allergy (IV) studies with further sensitizers from propolis and constituents common to propolis, poplar buds and balsam of Peru. *Contact Dermatit.* 1992;26:34-44.
133. Rudzki E, Grzywa Z, Bruo WS. Sensitivity to 35 essential oils. *Contact Dermatit.* 1976;2:196-200.
134. Foti C, Bonamonte D, Conserva A, et al. Allergic and photoallergic contact dermatitis from ketoprofen: evaluation of cross-reactivities by a combination of photopatch testing and computerized conformational analysis. *Curr Pharm Des.* 2008;14:2833-2839.
135. Matthieu L, Meuleman L, van Hecke E, et al. Contact and photocontact allergy to ketoprofen. The Belgian experience. *Contact Dermatit.* 2004;50:238-241.
136. Nakagawa M, Kawai K, Kawai K. Cross-sensitivity between resorcinol, resorcinol monobenzoate and phenyl salicylate. *Contact Dermatit.* 1992;27:199-200.
137. Bruze M. A nonrelevant contact allergy to balsam of Peru as an indication of a relevant contact allergy to phenol-formaldehyde resin. *Am J Contact Dermat.* 1994;5:162-164.
138. Bruze M, Andersen KE, Goossens A. Recommendation to include fragrance mix 2 and hydroxyisohexyl 3-cyclohexene carboxaldehyde (Lyrall) in the European baseline patch test series. *Contact Dermatit.* 2008;58:129-133.
139. Johansen JD, Rastogi SC, Menné T. Exposure to selected fragrance materials. A case study of fragrance-mix-positive eczema patients. *Contact Dermatit.* 1996;34:106-110.
140. Johansen JD, Rastogi SC, Andersen KE, Menné T. Content and reactivity to product perfumes in fragrance mix positive and negative eczema patients. *Contact Dermatit.* 1997;36:291-296.
141. Johansen JD, Frosch PJ, Rastogi SC, Menné T. Testing with fine fragrances in eczema patients: results and test methods. *Contact Dermatit.* 2001;44:304-307.
142. Rudzki E, Grzywa Z. Balsam of Peru as screening agent for essential oils sensitivity. *Dermatologica.* 1977;155:115-121.
143. Trattner A, David M. Patch testing with fine fragrances: comparison with fragrance mix, balsam of Peru and a fragrance series. *Contact Dermatit.* 2003;49:287-289.
144. Baxter KF, Wilkinson SM, Kirk SJ. Hydroxymethyl pentylcyclohexene-carboxaldehyde (Lyrall) as a fragrance allergen in the UK. *Contact Dermatit.* 2003;48:117-118.
145. The Good Scents Company Information System. <http://www.thegoodscentscompany.com/data/rw1020041.html>. Accessed February 18, 2019.
146. Vejanurug P, Tresukosol P, Sajjachareonpong P, Puangpet P. Fragrance allergy could be missed without patch testing with 26 individual fragrance allergens. *Contact Dermatit.* 2016;74:230-235.
147. van Oosten EJ, Schuttelaar ML, Coenraads PJ. Clinical relevance of positive patch test reactions to the 26 EU-labelled fragrances. *Contact Dermatit.* 2009;61:217-223.
148. Bennike NH, Zachariae C, Johansen JD. Non-mix fragrances are top sensitizers in consecutive dermatitis patients—a cross-sectional study of the 26 EU-labelled fragrance allergens. *Contact Dermatit.* 2017;77:270-279.
149. de Groot AC, Schmidt E. Tea tree oil: contact allergy and chemical composition. *Contact Dermatit.* 2016;75:129-143.
150. de Groot AC, Schmidt E. *Essential Oils: Contact Allergy and Chemical Composition.* Boca Raton, FL: CRC Press, Taylor and Francis Group; 2016.
151. Deza G, García-Bravo B, Silvestre JF, et al. Contact sensitization to limonene and linalool hydroperoxides in Spain: a GEIDAC\* prospective study. *Contact Dermatit.* 2017;76:74-80.
152. Matura M, Goossens A, Bordalo O, et al. Patch testing with oxidized R-(+)-limonene and its hydroperoxide fraction. *Contact Dermatit.* 2003;49:15-21.



153. Bråred Christensson J, Andersen KE, Bruze M, et al. An international multicentre study on the allergenic activity of air-oxidized *R*-limonene. *Contact Dermatitis*. 2013;68:214-223.
154. Karlberg AT, Dooms-Goossens A. Contact allergy to oxidized *d*-limonene among dermatitis patients. *Contact Dermatitis*. 1997;36:201-206.
155. Matura M, Skold M, Börje A, et al. Not only oxidized *R*(+)- but also *S*(-)-limonene is a common cause of contact allergy in dermatitis patients in Europe. *Contact Dermatitis*. 2006;55:274-279.
156. Veien NK, Hattel T, Justesen O, Nørholm A. Oral challenge with balsam of Peru in patients with eczema: a preliminary study. *Contact Dermatitis*. 1983;9:75-76.
157. Veien NK, Hattel T, Justesen O, Nørholm N. Oral challenge with balsam of Peru. *Contact Dermatitis*. 1985;12:104-107.
158. Veien NK, Hattel T, Justesen O, Nørholm A. Reduction of intake of balsams in patients sensitive to balsam of Peru. *Contact Dermatitis*. 1985;12:270-273.
159. Veien NK, Hattel T, Justesen O, Nørholm A. Dietary restrictions in the treatment of adult patients with eczema. *Contact Dermatitis*. 1987;17:223-227.
160. Veien NK, Hattel T, Laurberg G. Can oral challenge with balsam of Peru predict possible benefit from a low-balsam diet? *Am J Contact Dermat*. 1996;7:84-87.
161. Niinimäki A. Delayed-type allergy to spices. *Contact Dermatitis*. 1984;11:34-40.
162. Niinimäki A. Double-blind placebo-controlled peroral challenges in patients with delayed-type allergy to balsam of Peru. *Contact Dermatitis*. 1995;33:78-83.
163. Salam TN, Fowler JF Jr. Balsam-related systemic contact dermatitis. *J Am Acad Dermatol*. 2001;45:377-381.
164. Srivastava D, Cohen D. Identification of the constituents of balsam of Peru in tomatoes. *Dermatitis*. 2009;20:99-105.
165. Paulsen E, Christensen LP, Andersen KE. Tomato contact dermatitis. *Contact Dermatitis*. 2012;67:321-327.
166. Wolf R, Orion E, Ruocco E, Baroni A, Ruocco V. Contact dermatitis: facts and controversies. *Clin Dermatol*. 2013;31:467-478.
167. Kulberg A, Schliemann S, Elsner P. Contact dermatitis as a systemic disease. *Clin Dermatol*. 2014;32:414-419.
168. Belsito DV. Surviving on a balsam-restricted diet: cruel and unusual punishment or medically necessary therapy? *J Am Acad Dermatol*. 2001;45:470-472.
169. Scheman A, Rakowski EM, Chou V, Chhatiwala A, Ross J, Jacob SE. Balsam of Peru: past and future. *Dermatitis*. 2013;24:153-160.
170. The PubChem Project. (2E)-3-(4-Hydroxy-3-methoxyphenyl)prop-2-en-1-yl benzoate. <https://pubchem.ncbi.nlm.nih.gov/compound/6441293>. Accessed February 18, 2019.
171. Bruze M, Condé-Salazar L, Goossens A, Kanerva L, White IR. Thoughts on sensitizers in a standard patch test series. The European Society of Contact Dermatitis. *Contact Dermatitis*. 1999;41:241-250.

**How to cite this article:** de Groot AC. *Myroxylon pereirae* resin (balsam of Peru) – A critical review of the literature and assessment of the significance of positive patch test reactions and the usefulness of restrictive diets. *Contact Dermatitis*. 2019;80:335–353. <https://doi.org/10.1111/cod.13263>